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ABSTRACT OF DISSERTATION 
 
 
ADDITIVES TO CONTROL MECHANICAL PROPERTIES AND DRUG DELIVERY OF INJECTABLE 
POLYMERIC SCAFFOLDS 
In situ forming implants (ISIs) are popular due to their ease of use and local drug delivery 
potential, but they suffer from high initial drug burst, and release behavior is tied closely to 
solvent exchange and polymer properties. Additionally, such systems are traditionally viewed 
purely as drug delivery devices rather than potential scaffold materials due to their poor 
mechanical properties and minimal porosity. The aim of this research was to develop an 
injectable ISI with drug release, mechanical, and microstructural properties controlled by micro- 
and nanoparticle additives.  
First, an injectable ISI was developed with appropriate drug release kinetics for 
orthopedic applications. Poly(β-amino ester) (PBAE) microparticles were loaded with simvastatin 
or clodronate, and their loading efficiency and drug retention after washing was quantified. 
Drug-loaded PBAE microparticles and hydroxyapatite (HA) microparticles were added to a 
poly(lactic-co-glycolic acid) (PLGA)–based ISI. By loading simvastatin into PBAE microparticles, 
release was extended from 10 days to 30 days, and burst was reduced from 81% to 39%.  
Clodronate burst was reduced after addition of HA, but was unaffected by PBAE loading. 
Scaffold mass and porosity fluctuated as the scaffolds swelled and then degraded over 40 days.  
 Next, the mechanical properties of these composite ISIs were quantified. Both micro- 
and nanoparticulate HA as well as PBAE microparticle content were varied. Increasing HA 
content generally improved compressive strength and modulus, with a plateau occurring at 30% 
nano-HA. Injectability remained clinically acceptable for up to 10% w/w PBAE microparticles. Ex 
vivo injections into trabecular bone improved both strength and modulus. 
 Lastly, HA-free ISIs were investigated for drug delivery into the gingiva to treat 
periodontitis. Doxycycline and simvastatin were co-delivered, with delivery of doxycycline over 1 
week accompanied by simvastatin release over 30 days. PBAE-containing ISIs exhibited higher 
initial and progressive porosity and accessible volume than PBAE-free ISIs over the course of 
degradation. Additionally, PBAE-containing ISIs provided superior tissue retention within a 
simulated periodontal pocket. The ISIs investigated here have a wide range of potential 
applications due to their flexible material and drug release properties, which can be controlled 
by both the chemistry and concentration of various particulate additives.  
KEYWORDS: Injectable tissue engineering scaffolds, biodegradable polymers, controlled drug 
delivery, biodegradable hydrogels, in situ forming drug delivery implant 
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Chapter 1 Introduction 
 In situ forming implants (ISIs) made from poly(lactic-co-glycolic acid) (PLGA) have been 
thoroughly investigated for drug delivery applications, and these systems have been 
commercialized due to their simplicity and effectiveness as sustained, local drug delivery depots. 
The release kinetics from these systems are generally controlled by modifying the polymer or 
solvent used, but very little information is available on the impact that particulate additives may 
have on the material properties and release kinetics. In particular, PLGA ISIs are not favored for 
applications requiring tissue ingrowth or mechanical support because their microarchitecture and 
mechanical properties are inferior to pre-formed scaffolds. Here, composite 
PLGA/hydroxyapatite/hydrogel ISIs were developed for orthopedic applications, and 
PLGA/hydrogel ISIs were also further investigated for soft tissue applications. 
 Chapter 2 provides a brief history of synthetic biodegradable polymers used for drug 
delivery, and includes properties of some of the most popular materials. Then, the applications 
for these materials are discussed, and particular focus is placed on micro- and nanoparticle 
systems, as well as the different types of ISIs. Next is an overview of two conditions that were 
targeted in this research – osteonecrosis of the femoral head and periodontitis. The specific aims 
of this dissertation conclude Chapter 2. 
 Chapters 3 and 4 are both related to the development of a locally injectable PLGA ISI 
suitable for orthopedic applications. The work in Chapter 3 is devoted to quantifying the effects 
of hydrogel and hydroxyapatite additives on drug release from a PLGA ISI. A significant portion of 
this chapter focused on developing drug-loaded, hydroxyapatite-coated, hydrogel microparticles. 
The objective of this chapter was to demonstrate that particulate additives could modify release 
kinetics and provide a suitable microarchitecture for trabecular bone augmentation. Chapter 4 
focused on the effects of hydroxyapatite and hydrogel particles on the material properties of the 
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system. Specifically, mechanical properties and injectability were quantified, and injection into 
artificial bone and ex vivo bone samples were used to demonstrate feasibility of the system as a 
mechanically supportive, injectable scaffold. 
 In Chapter 5, PLGA ISIs containing a high concentration of hydrogel microparticles were 
investigated for soft tissue applications, and the periodontal pocket was considered the target 
tissue. Here, hydrogels were processed into microparticles using a wet grinding technique without 
using hydroxyapatite additives. The purpose of adding hydrogel was to improve the space-filling, 
microarchitecture, and co-delivery of an antibiotic and osteogenic drug. The objective of this 
chapter was to show the potential of these materials for future consideration as tissue scaffolds.    
 
 
 
 
 
 
 
 
 
 
 
Copyright © Paul Daniel Fisher 2014  
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Chapter 2 Background and Significance 
2.1. Synthetic biodegradable polymers for drug delivery 
 Biomaterials are classically defined, distinctly from drugs, as materials used to augment 
or replace tissues or processes in the body. With the advent of synthetic, biodegradable polymers, 
however, the line becomes blurred, as these materials are capable of blending the roles of 
biomaterials and drugs into a single system [1]. The recognition that certain polymers containing 
hydrolytically or enzymatically labile groups could be degrade naturally after implantation led to 
a revolution in the field of drug delivery [2-8]. By incorporating drugs into a biodegradable 
polymer matrix, spatial and temporal control of release kinetics was possible. As seen in Figure 
2.1, the publication rate for biodegradable polymeric drug delivery systems has grown 
exponentially since their first uses in the 1970s. This growth is due in no small part to the vast 
array of synthetic polymer properties that can be controlled by both chemical syntheses and 
material processing steps, resulting in an extremely versatile platform. Controlling and 
understanding mechanisms by which these polymers degrade is important when designing or 
choosing a material for drug delivery, because the degradation behavior influences drug release 
rates and host response [9]. Some of the most popular materials and their potential applications 
are presented in the subsequent sections, with an emphasis placed on their mechanisms and rates 
of degradation.  
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Figure 2.1. Annual publications containing the search terms “polymer” and “drug delivery.” Via 
PubMed. 
2.1.1. Polyanhydrides 
Polyanhydrides are named for the anhydride bonds that link repeating units of the 
polymer backbone (Figure 2.2A), and were originally synthesized in the early 1980s with the 
objective of matching polymer degradation rate to drug release [10]. The anhydride bonds can be 
hydrolyzed to produce dicarboxylic acids, and these materials degrade through surface erosion, 
as the water uptake rate is generally far lower than the rate of surface chain scission [11]. As a 
result of this degradation mechanism, linear drug release rates that closely match the material 
degradation rate can be achieved [10, 12]. Since the bulk of the polymer does not appreciably 
hydrate as it degrades, processing methods that affect the microstructure or the implant 
geometry can strongly influence degradation kinetics by limiting or increasing the accessible 
surface area [13, 14]. Copolymers of polyanhydrides are also used to control the properties of 
these materials. For example, polyanhydrides copolymerized with more hydrophilic blocks can be 
produced to accelerate degradation and drug release from months to hours [10, 13, 15-17], while 
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poly(anhydride-co-imides) possess mechanical properties more suitable for orthopedic 
applications [18]. Polyanhydrides have been further modified via cross-linking to improve 
mechanical strength [19, 20]. The incorporation of hydroxyapatite (HA) via surface-grafting can 
promote bone cell attachment, and homogeneously incorporated HA can improve mechanical 
properties [20, 21]. Polyanhydrides have exhibited good biocompatibility in animal in vivo studies, 
with no observed toxicity, inflammation, or other adverse effects noted after implantation in a 
variety of tissues [22-25]. The FDA first approved their use in 1996 in the form of Gliadel®, a 
polyanhydride wafer loaded with chemotherapeutic carmustine, which is placed directly onto 
brain tissue after removal of cancerous tumors. 
2.1.2. Poly(lactic-co-glycolic acid) 
 The most well-characterized and prevalent biodegradable polymers in drug delivery are 
composed of lactic or glycolic acid subunits, forming poly(lactic acid) (PLA), poly(glycolic acid) 
(PGA), or poly(lactic-co-glycolic acid) (PLGA) (Figure 2.2B). Investigation of these polymers began 
in the 1970s with PLA [3, 26, 27]. Because the monomers in PLA possesses methyl side groups, 
optically pure, semicrystalline polymers made from either D or L enantiomers can be produced, 
but PLA is most commonly used in drug delivery in amorphous form as the product of a racemic 
mixture [28]. PGA is highly crystalline, though it is hydrolyzed rapidly compared to PLA due to its 
more hydrophilic nature, and as a homopolymer was popularized as the first biodegradable 
synthetic suture, Dexon® [29]. PLGA is generally amorphous, and degradation times are highly 
dependent on the lactide:glycolide ratio [29-32]. As with most degradable polymers, the 
degradation rate also decreases with molecular weight [33]. PLGA containing a 50:50 
lactide:glycolide ratio degrades most rapidly, and degradation time can be modified by varying 
molecular weight, hydrophilicity of the chain end species, or the lactide:glycolide ratio [33, 34]. 
PLGA, PLA, and PGA are primarily bulk-degrading because the polymer chains are hydrophilic 
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enough to allow water penetration before surface erosion occurs, so a progressive molecular 
weight decrease occurs throughout the material [32]. Chain scission eventually produces lactic 
and glycolic acid, both of which are endogenously produced during metabolic processes, and 
soluble acidic oligomers may autocatalyze degradation [35, 36]. PLA and PLGA are used in many 
commercial drug delivery systems, including antibiotic delivery (Atridox®, Arestin®), hormone 
therapy (Nutropin®), and cancer treatment (Lupron Depot®, Trelstar Depot®, Eligard®).  
2.1.3. Poly(caprolactone) 
 Poly(caprolactone) (PCL) is a biodegradable, semi-crystalline polymer characterized by its 
hydrophobicity, long degradation time, and low melting point (Figure 2.2C). PCL was one of the 
earliest polymers investigated as a degradable biomaterial, and was originally tested as a 
biodegradable alternative to silicon rubber implants for long-term delivery of contraceptives in 
the 1970s [5, 37]. However, its usefulness as a homopolymer was limited due to its 2-4 year 
degradation time [38]. Because it is easily blended or copolymerized, PCL is often used to produce 
copolymers or polymer blends with versatile rheological, viscoelastic, and drug release properties 
that depend on the ratios of each component [39-43]. The glass transition temperature of PCL is 
around -60˚C, meaning PCL is far more flexible and less brittle than PLGA and PLA at ambient and 
physiological temperatures, which can improve physical properties of blends and copolymers [44-
46]. Additionally, its low melting temperature (approximately 60˚C) makes PCL one of the more 
workable materials, so it is a popular choice for 3-D printing, extrusion, and melt blending [47-
50]. Amphiphilic copolymers of PCL and poly(ethylene glycol) (PEG) or other hydrophilic 
components have been investigated as solid particles, hydrogels, or micelles, with the highly 
hydrophobic PCL regions appropriate for sustained delivery of hydrophobic drugs [51-53]. The 
physical properties of PCL allow it to be easily blended with particle additives and formed into 
scaffolds with complex geometries, and PCL composites containing HA or other bioceramics have 
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been extensively investigated for orthopedic applications, although their lower mechanical 
properties limit their load-bearing potential [49, 54-57]. A block copolymer of PCL and PGA, now 
marketed as Monocryl®, was developed to reduce the stiffness of resorbable PGA sutures.  
2.1.4. Poly(ortho esters) 
In the 1980s, poly(ortho esters) (POEs), along with polyanhydrides, were among the first 
polymers specifically synthesized for drug delivery [58]. The ortho ester bonds (Figure 2.2D) result 
in more hydrophobic polymer chains than carbonyl-containing polymers such as PLGA, slowing 
water penetration and limiting hydrolysis to the polymer-water interface. This results in a pH-
sensitive, surface-eroding material that produces low-molecular weight, soluble byproducts, 
although longer-degrading POEs will eventually become permeated with water. Degradation rates 
can be further controlled by the incorporation of glycolic acid or other acidic species into the 
polymer backbone to autocatalyze degradation [59-61]. Conversely, surface erosion can be 
prolonged by incorporating basic excipients with poor water solubility to stabilize the polymer 
and prevent water imbibition [62]. During synthesis, the concentration of flexible diols and acid 
diols used in the polymer backbone determines the glass transition temperature, so very brittle 
or semi-solid POEs can be easily produced [63]. The latest generation of POEs have been 
specifically investigated as intraocular delivery systems because they are a viscous, easily 
injectable liquid at room temperature yet still provide erosion-based drug release [64, 65]. 
Because POEs are surface-eroding, they offer an advantage over PLA and PCL because small-
molecule, hydrophilic drugs can be released concomitantly with degradation as long as a 
stabilizing excipient is used [66]. 
2.1.5. Poly(β-amino esters) 
 Poly(β-amino esters) (PBAEs) are a class of biodegradable polymers that are synthesized 
through a condensation reaction between a diacrylate and a primary amine (Figure 2.2E) or 
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secondary-secondary diamine [67, 68]. This initial reaction occurs through a step-growth 
polymerization process, and a molar excess of diacrylate will produce acrylate-terminated 
macromers [69]. These macromers can be cross-linked using free radical initiated chain-growth 
polymerization to form hydrogels that can biodegrade at their ester bonds [69-71]. Many factors 
determine the degradation rate and swelling behavior of these hydrogels in aqueous 
environments, including diacrylate and amine chemistry, macromer synthesis time and 
temperature, and cross-link density [69-71]. PBAEs have been extensively investigated for their 
potential in DNA therapy. For example, PBAEs incorporated into PLGA microparticles were shown 
to improve loading efficiency and delivery of plasmid DNA, preserve integrity of the delivered 
plasmid DNA, and improve transfection efficiency [72-74]. Microparticulate copolymers of PBAE 
and PEG have been investigated for pH-sensitive delivery of drugs to cancer cells [75-77], and 
PBAE hydrogels have been investigated as both passive porogens and drug delivery vehicles [78-
82].  
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Figure 2.2. Chemical structures of common synthetic biodegradable polymers. A) Polyanhydride. 
B) Poly(lactic-co-glycolic acid). C) Poly(caprolactone). D) A simple ortho ester. Poly(ortho esters) 
tend to contain repeated cyclic units and therefore have a variety of possible structures. E) Poly(β-
amino ester) synthesized using a primary amine. 
2.2. Injectable drug delivery systems 
 As biodegradable polymers gained traction as versatile drug delivery platforms, research 
began to focus on improving the structure of these materials to simplify implantation and take 
advantage of their long lifespan in vivo. Pre-formed, monolithic implants require surgical 
implantation at the treatment site, and this approach is undesirable or even impossible for 
targeted treatments such as drug delivery to intratumoral or intraosseous tissue. Two distinct 
approaches to this problem are discussed below. First, drug-loaded polymeric micro- or 
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nanoparticles allow targeted delivery of biodegradable polymers via simple injection. Second, 
injections containing drug-loaded liquid precursors designed to solidify in situ permit formation 
of a monolithic implant at the injection site.   
2.2.1. Micro- and nanoparticle delivery 
Micro- and nanoparticles can be synthesized using a variety of techniques. Most 
commonly, the polymer is dissolved in an appropriate solvent, and is subjected to a series of 
emulsion steps that both entrap drug and stabilize spherical polymer droplets as they solidify 
during solvent evaporation. For hydrophilic drugs, a water/oil/water double emulsion technique 
is used. First, an aqueous drug solution is dispersed in the polymer/solvent phase (W1/O emulsion 
1). Next, the W1/O phase is emulsified in a second aqueous phase, creating a W1/O/W2 emulsion, 
and solid particles can be created through solvent removal. Frequently, surfactants are used to 
stabilize these emulsions, preventing collapse or coalescence of particles prior to solidification. 
For hydrophobic drugs, a single emulsion technique is sufficient, with the drugs added directly to 
the polymer phase, skipping the W1/O emulsion. Particle size can be controlled by adjusting the 
solvent:water ratios, the surfactant content, temperature, and stirring parameters throughout 
the process [83-87].  
Microparticles can be created from films or slabs of material by simple grinding followed 
by sieving to the desired particle size, although this works best for weak, brittle materials.[88] 
Stronger materials are difficult to mechanically break apart, while soft or sticky materials such as 
PBAE hydrogels will re-aggregate during the grinding process, necessitating a powder additive to 
act as a dispersant. For particles that swell in water or other solvents without degrading quickly, 
drugs can be more easily loaded after particle formation by swelling the particles in a drug solution 
followed by solvent removal [81, 89-91]. This list of methods is by no means exhaustive – many 
other techniques have been developed to create drug-loaded micro- and nanoparticles beyond 
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these popular few listed, including spray drying [92-95], hot melt microencapsulation [96], phase 
inversion microencapsulation [97], non-aqueous solvent removal [98],  and interfacial 
polymerization [99, 100]. 
One major advantage of using a microparticle carrier is that particles can easily be injected 
as a powder or aqueous suspension to the target site. For example, Arestin® is the product name 
of a PLGA microparticle system, approved in 2001, containing the antibiotic minocycline. Arestin 
is injected as a powder directly into periodontal pockets to treat infection, and can achieve up to 
21 days of continuous drug release. Similarly, Lupon Depot ® is another PLGA microsphere-based 
system that was FDA-approved in 1989 for the treatment of prostate cancer, and is capable of 
delivering leuprolide acetate for 30 days.  However, the properties of micro- and nanoparticles do 
not always behave consistently with monolithic implant degradation and release kinetics. First, 
particles have a much higher surface area to volume ratio, and thus the rate of water permeation 
is increased. For surface eroding polymers such as poly(anyhydrides) and poly(ortho esters), this 
means a faster, but generally still linear, release rate occurs since there is a larger polymer:water 
interface for a given mass of material. For bulk degrading polymers such as PLGA, this means a 
burst effect is often seen as the material hydrates much more rapidly, and diffusive release is 
accelerated due to the smaller diffusion distance required to escape the material [101].  
2.2.2. In situ forming implants 
 Compared to micro- or nanoparticle systems, in situ forming implants (ISIs) are simpler, 
with fewer and less costly fabrication steps, and 100% encapsulation efficiency [102, 103]. The 
principle underlying all ISIs is that a precursor solution or mixture can be injected at the treatment 
site, and this mixture can be induced or will passively adopt a solid form, resulting in a monolithic 
delivery system at the site of injection. Typical shortcomings of such systems include the 
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propensity for burst release during the solidication period, toxicity of any additives required for 
solidification (solvents, heat, or initiators), and heterogeneity of the ISI microstructure [102, 103].  
2.2.3. Thermoplastics 
 Thermoplastics used as ISIs are polymers with a relatively low melting point, which 
enables them to be injected as a melt and solidify upon cooling to body temperature. 
Thermoplastics are an appealing choice for ISI because no solvents or chemical initiator is required 
to solidify. Initial attempts to develop a thermoplastic ISI focused on block copolymers of PEG and 
PLA and blends of L-PLA and PCL, however these materials exhibited melting or glass transition 
points around 60˚C, which can cause pain, tissue necrosis, and scar tissue formation [104]. 
Additionally, such systems exhibited slow release, with less than 50% drug released by 30 or 60 
days, depending on the material. Blending PCL with methoxyPEG was able to reduce the melting 
temperature [105]. Poly(ortho esters) have also been investigated as thermoplastic ISIs, because 
low-molecular weight POEs can be created with low viscosity at ambient temperatures [106]. POE 
ISIs have been copolymerized with PLA or PGA to accelerate degradation and allow autocatalysis 
of hydrolysis [107]. Thermoplastics have been most thoroughly investigated for drug delivery into 
tumors because the local hyperthermia can be utilized as treatment, rather than a disadvantage.  
2.2.4. Sol-gel transitioning materials 
 Sol-gels refer to materials that undergo a solution to gel phase transition due to a rise in 
temperature that shifts the hydrogen bonding equilibrium from water-polymer to polymer-
polymer [108]. The temperature at which this transition occurs is referred to as the lower critical 
solution temperature (LCST), and this kinetics with which this phenomenon occurs can affect the 
initial drug burst [109]. Poly(N-isopropyl acrylamide) (PNIPAAM) is one of the most studied sol-
gels due to its rapid phase transition and its natural LCST of 32˚C, which can be adjusted to 37˚C 
through additives [110-112]. Unfortunately, cell toxicity and platelet activation hinder PNIPAAM 
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as a potential implantable material, and it must be copolymerized to become biodegradable [113, 
114]. Copolymerizing PNIPAAM with known biodegradable species can allow hydrolytic 
degradation into oligomers small enough to be cleared [115, 116]. Poly(ethylene oxide) (PEO) and 
poly(propylene oxide) (PPO) have been investigated in the form PEO-PPO-PEO  triblock 
copolymers, called Poloxamers, which undergo the sol-gel transition at a temperature dependent 
upon the polymer concentration [117]. Most popular in this family of copolymers is Poloxamer 
407 (Pluronic® F127), which has been well-tolerated after implantation in animals [118, 119]. 
However, Pluronic® F127 tends to disintegrate rapidly, limiting release to hours or days, and the 
gel transition temperature and rate is susceptible to additives, including drugs [120, 121]. PCL-
PEG copolymers and PEG-PLGA-PEG triblock copolymers have been investigated because the 
gelling temperature is easily controlled by varying PEG content, and have garnered interest due 
to their low observed toxicity [122-124]. 
2.2.5. Cross-linking systems 
 In situ cross-linking systems differ from the previous in situ forming materials because an 
additional stimulus is required to promote solidification. The stimulus can be heat, light, an ionic 
species, or a reactive chemical [102]. Thermosets, which require heat as well as a chemical 
initiator, are cured irreversibly as the cross-linking reaction proceeds. These systems have many 
safety considerations before they can be considered, including heat generated, free radical 
production, and toxicity of the monomers present in the prepolymer [103]. As such, relatively 
little academic research is available on thermosets as biodegradable ISIs for drug delivery 
applications, though several patents have explored the concept [125-127]. Photocrosslinked 
polymers are advantageous because they can be rapidly polymerized via fiber optic cables 
inserted during the injection, or by a penetrating light source, without excess heat needed. 
Similar, non-degradable photocrosslinked materials have historically been used in dentistry for 
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many years [128]. An ISI created by cross-linking a PEG-containing, acrylate-terminated polymer 
with the photonitiator 2,2-dimethoxy-2-phenylacetophenone (DMPA), resulted in hydrogels with 
significant tensile strength that released the (now discontinued) antibiotic sulfamethoxazole over 
3 days [129]. PLA modified to allow cross-linking has been researched as an orthopedic material, 
and PEG-based cross-linked hydrogels have been developed for protein release [130, 131]. 
Photocrosslinked polymers can be difficult to fully polymerize, because irregular geometry and 
the presence of tissue limits light penetration, and just as in thermally cross-linked polymers, the 
generation of free radicals can have toxic side effects. Furthermore, short-wavelength UV 
irradiation rapidly damages tissues and is a known carcinogen, though even long-wave UV sources 
are potentially carcinogenic [132]. Chemically cross-linked polymers begin polymerizing 
immediately after addition a cross-linking reagent to the prepolymer, and as such are unique 
among these in situ forming systems because they have a setting time that begins prior to 
injection. Thiol-containing, PEG-based polymers were cross-linked into hydrogels within 3 
minutes using a divinylsulfone-based cross-linking reagent, and these hydrogels were capable of 
releasing a model protein, bovine serum albumin, for 20 days [133]. For chemically cross-linked 
ISIs, monomer and initiator toxicity are of concern because the process generally proceeds more 
slowly than thermal- or photocrosslinking, which can allow these species to leach out of the 
injectate. Physically cross-linked materials are unique in that instead of creating covalent cross-
links via an initiator, the prepolymer forms strong physical associations that cause solidification. 
Although not a synthetic material, one of the best examples of these materials is alginate, which 
can utilize divalent cations (typically calcium) to form a physically cross-linked gel from a precursor 
solution. Generally, physiological conditions do not have sufficient calcium concentrations to 
promote gelation, so calcium can be co-delivered in temperature-sensitive vesicles that release 
calcium at body temperature, resulting in gelation shortly after injection [134, 135]. However, 
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because the vesicles had poor shelf-stability, the formulation would gradually gel prematurely as 
calcium was slowly released even at low temperatures. An interesting application for injectable 
alginate systems is ocular drug delivery, because fluids in the eye possess sufficient calcium 
chloride concentrations to permit gelation. Such a system was able to release pilocarpine, a 
glaucoma treatment, over 24 hours [136]. Degradation of alginate can be unpredictable because 
these hydrogels are sensitive to ionic and pH fluctuations.  
2.2.6. Solvent exchange 
 Phase inversion occurs when a hydrophobic polymer dissolved in a water-miscible solvent 
is introduced to an aqueous environment. This process is appealing for drug delivery systems 
because the formulation is quite simple, and a wide variety of polymers can be utilized. A drug is 
freely mixed into the dissolved polymer, and upon injection, the polymer immediately begins to 
precipitate, entrapping drug in the solid phase as solvent exchange occurs. However, drug release 
is characterized by an initial burst, especially for hydrophilic drugs, because drug can easily escape 
during solvent exchange prior to complete solidification. PLA and PLGA are the two most popular 
materials for phase inverting ISIs, and they are used in two FDA-approved delivery systems – 
Atridox® and Eligard®. Many factors can influence the microstructure and drug release kinetics of 
these ISIs: choice of polymer, polymer concentration and molecular weight, water miscibility of 
solvent, and the size and hydrophilicity of the drug [137-141]. Generally, highly water-miscible 
solvents such as N-methyl-2-pyrrolidone (NMP) are used because they allow rapid solidification, 
yet this also contributes to higher burst release and a hetereogeneous microstructure, as surface 
solidification occurs more rapidly [142]. Such systems exhibit elongated pores oriented radially 
towards the surface, as well as an outer, low-porosity “skin” layer [137, 143]. Solvents with low 
miscibility, such as benzyl benzoate or triacetin, cause lower burst and longer release periods as 
well as more spherical, uniformly-distributed pores [137, 143]. There is evidence that these 
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hydrophobic solvents may lead to the formation of an intermediate gel phase that gradually 
solidifies [144, 145]. However, these slow-forming systems can take days or weeks to solidify, and 
the semisolid implants with liquid cores can rupture if they are subjected to stresses. Increasing 
polymer concentration slows drug release by forming a thicker “skin” layer, which hampers drug 
diffusion as well as solvent exchange [142, 146]. Increasing polymer concentration will also 
increase the viscosity of the system and slow solidification. Hydrophilic, small-molecule drugs are 
the most challenging to control in these systems, because a large initial burst occurs during 
solvent exchange, while proteins or hydrophobic small molecule drugs are entrapped in the solid 
phase more efficiently and exhibit lower burst. ISIs formed by phase inversion comprise the focus 
of the subsequent chapters.  
2.3. Clinical applications for in situ forming systems 
ISIs can be utilized in two different ways: either the ISI can be injected with the objective 
of sustained, systemic delivery of drugs, or it can be injected into a target tissue to provide a local 
treatment with limited systemic availability. A specific focus will be made on solvent-exchange 
systems, as these are the foundation of this work, and several commercially available and 
preclinical forms are currently available. Because PLGA is present in many FDA-approved 
formulations, its clinical safety has been well-established, and the solvents used are considered 
nontoxic, with side effects limited to mild irritation [147]. By comparison, other in situ forming 
materials are still in their infancy, with many unknowns including material stability, in vitro vs in 
vivo behavior, and potential side effects. In particular, factors such as heat, free radicals, and 
potentially toxic polymer precursors or initiators are all components of other systems that require 
extensive research before they can be considered for clinical applications.  
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2.3.1. Systemic treatments 
 Systemic drug delivery can achieved from ISIs by injection into a tissue where the released 
drug can freely enter circulation. The subcutaneous route is most popular because it is easily 
accessed with a simple injection, and there is sufficient circulation and fluid flow to distribute the 
drug and clear the polymer as it degrades. ISIs for systemic drug delivery are advantageous 
because they can provide sustained delivery of a drug from a single injection (typically monthly), 
while a simple drug solution may require daily injections to maintain a therapeutic concentration 
[102]. Two technologies, both based on solvent exchange, are commercially available or in clinical 
trials. Eligard® is an FDA-approved treatment for advanced prostate cancer, which is composed 
of a PLGA solution in NMP that is mixed with leuprolide acetate prior to subcutaneous injection 
[148]. Previous treatments required daily subcutaneous injection of a leuprolide solution, while 
Eligard® is available in 1-month, 3-month, and 6-month formulations, with longer-lasting 
formulations containing PLGA at higher concentrations and with larger lactide:glycolide ratios. For 
patients with advanced prostate cancer, these infrequent treatments are an effective palliative 
treatment requiring minimal hospitalization time. Another systemic treatment utilizing solvent 
removal from PLGA ISIs is Relday™, which recently completed phase I clinical trials. Relday™ 
delivers risperidone from a subcutaneous or intramuscular implant in a once-monthly injection 
for the treatment of schizophrenia and bipolar disorder.   
2.3.2. Targeted therapies 
 Closer attention will be paid to targeted injections to treat specific tissues with local 
dosages, as ISIs offer potential advantages over existing technologies. Because they solidify upon 
injection, ISIs can be retained within the target tissue, while drug solutions or microparticle 
suspensions can potentially be cleared from the injection site due to natural fluid flow. Limiting 
systemic dosages is a major goal for modern targeted drug delivery systems, because it enables 
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lower overall drug loading (reducing cost), and reduces or eliminates side effects. As an example, 
expensive and potent growth factors such as bone morphogenetic protein 2 (BMP-2) can have 
severe side effects such as heterotopic ossification and tumor formation when they reach tissues 
outside the treatment area [149, 150]. A solid delivery depot could greatly reduce both treatment 
costs and the chance of these serious adverse effects by efficiently delivering drug only to the 
target tissue. This concept, in the form of a solvent-exchange ISI, has been explored in numerous 
research articles as well as one commercial product designed for the treatment of periodontitis. 
2.3.3. Periodontitis 
 Periodontitis is a term for inflammatory diseases oral tissue, specifically gingival tissue, 
alveolar bone, and ligamentous tissue all involved in tooth support [151]. In the United States 
alone, 48% of adults suffer from chronic periodontitis, and it is estimated that 90% of the world’s 
population is affected [151, 152]. Beyond its effects on oral health, periodontitis has also been 
implicated in development of systemic conditions such as cardiovascular disease, stroke, and 
diabetes [153, 154]. An initial buildup of bacteria that is not addressed properly by oral hygiene 
will eventually form larger colonies in gingival pockets residing below the gingival sulcus. These 
pockets, if left untreated, become periodontal pockets, in which the fibrous attachment of 
gingival tissue to the tooth is destroyed and destruction of alveolar bone occurs [151]. Bacteria 
adhering to the tooth surface can form a biofilm, called dental plaque, which begins as a sticky 
layer that hardens within 48 hours [155]. Once the plaque has hardened, it requires professional 
cleaning to reliably remove, and can act as a barrier that limits drug penetration to the underlying 
bacteria. The combination of a periodontal pocket and plaque barrier protect the bacteria and 
allow the infection to flourish, and the surrounding tissues exhibit inflammation and resorption 
due to the spreading bacterial front. Ultimately, as the fibrous tissue and alveolar bone is 
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destroyed, tooth loosening and loss will occur, and severe infections can spread beyond the oral 
cavity if they reach the bloodstream [151].  
 Treatment of periodontitis begins with a proper oral hygiene, which can halt the disease 
at its early stages [156]. Advanced periodontitis requires a deep, professional cleaning, termed 
scaling and root planing. Scaling is the removal of tartar (hardened plaque) from the tooth surface, 
and root planing is the process of smoothing the tooth root and removing infected tissue [157]. 
Together, these techniques are effective at combatting periodontitis, though infections can still 
persist and the missing tissue often fails to regenerate. Antibiotics are therefore frequently used 
as an adjuvant therapy in the treatment of advanced periodontitis where persistent infection can 
occur [158, 159]. Tetracyclines such as doxycycline are the most popular antibiotic for this disease, 
because they effectively inhibit the growth of A. actinomycetemcomitans, one of the most 
common bacteria involved in aggressive periodontitis, and are also lethal to other bacterial 
species [160, 161]. Doxycycline also has anti-matrix metalloproteinase (MMP) activity, therefore 
slowing or preventing the resorption of connective tissue [161-163]. This secondary anti-MMP 
effect occurs even at subantimicrobial doses, and has been shown to improve outcomes when 
combined with scaling and root planing [164]. Further, there is evidence that doxycycline has anti-
inflammatory and anti-bone resorptive properties [165-167]. Looking towards the future, an ideal 
treatment for periodontitis can be envisioned, in which local delivery of an antibiotic is coupled 
with restorative drugs (for example, an osteogenic agent to help regenerate lost alveolar bone). 
In cases where alveolar bone loss is extensive, tissue grafts as well as synthetic scaffolds have 
been employed to guide bone regeneration [168, 169]. Therefore, a single injection that provides 
drug delivery as well as scaffold potential can serve multiple purposes as a periodontitis 
treatment. Currently, a solvent removal-based ISI, Atridox®, is commercially available as a 
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sustained local doxycycline treatment that is injected directly into the periodontal pocket after 
scaling and root planing.  
2.3.4. Osteonecrosis of the femoral head 
 Osteonecrosis of the femoral head is the death of bone tissue in the proximal femoral 
epiphysis, generally due to an interruption in blood supply. An estimate from the 1990s indicated 
that osteonecrosis of the femoral head affects over 10,000 new patients each year in the United 
States, and is also responsible for more than 10% of all hip arthroplasties annually [170]. A more 
recent study in Korea found that the incidence of confirmed diagnoses nearly doubled between 
2002 and 2006, with prevalence rising from 20 per 100,000 to 38 per 100,000 [171]. There are 
many identified risk factors, including chronic steroid use, alcohol use, trauma, and smoking, and 
up to 10-25% of cases are idiopathic [172]. Most of the blood supply to the femoral head comes 
from the large branch of the medial femoral circumflex artery and smaller branches of the lateral 
femoral circumflex artery. The superior and inferior gluteal arteries and the ligamentum teres also 
contribute to the epiphyseal vasculature [173]. Though the exact mechanism causing progression 
of osteonecrosis is unclear, it is believed that infarction in some of these blood sources can lead 
to cell necrosis as well as pathological apoptosis of osteoblasts and osteocytes [174]. As a result, 
the balance between osteoclast and osteoblast activity is disrupted, resulting in proportionally 
more resorption. Because the femoral head is weight-bearing, microfractures due to 
osteonecrosis can easily propagate and lead to structural collapse. Osteonecrosis in the femoral 
head begins asymptomatically, then appears as a small, crescent-shaped region of radiolucency 
adjacent to the weight-bearing region at the articular surface. This region progresses to a 
flattened or otherwise deformed femoral head as the bone collapses, and this process is 
associated with pain and stiffness in the joint [170, 175-177]. If osteonecrosis is diagnosed in the 
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early stages, before collapse has occurred, there are surgical options that have had varying 
degrees of success.  
The most common treatment for osteonecrosis of the femoral head is core 
decompression, which has a success rate inversely proportional to the amount of necrosis, with 
“success” determined as halting or reversing the progression of the disease [178]. However, 
patients with successful intervention are still subject to recurrence, as well as elevated rates of 
osteoarthritis and eventual arthroplasty later in life [179, 180]. A major issue with the treatment 
options for osteonecrosis is that a diagnosis is frequently not made until the condition has already 
progressed to a stage where collapse is inevitable. Core decompression is thought work by 
alleviating high pressure and promoting a bone healing response to the removed tissue, but it 
does not rescue mechanically compromised bone. Recent research has focused on 
pharmaceutical intervention using targeted delivery systems to treat osteonecrosis. Patients 
receiving systemic bisphosphonate treatments to inhibit resorption had better outcomes if their 
disease was still in the early stages, although follow-up studies have had mixed results regarding 
incidence of arthroplasties within two years following treatments [181-184]. Contemporary 
research has utilized a targeted injection of bisphosphonate solution to prevent systemic 
exposure, as well as the addition of BMP-2 to the injection to promote osteogenesis, with 
promising results.[185, 186] However, there were issues with heterotropic ossification, indicating 
that the injection was not fully retained within the femoral head [186]. Recently, an injectable 
system for co-delivery of clodronate and simvastatin was also developed for the treatment of 
pediatric idiopathic osteonecrosis [90]. Clodronate is a bisphosphonate whose mechanism of 
action causes apoptosis of osteoclasts, while simvastatin has recently been extensively studied 
for its upregulation of BMP-2 to promote bone regeneration [187-190]. ISIs have not been 
investigated for treatment of these diseases, and they traditionally have low porosity and poor 
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mechanical properties. However, the femoral head is an interesting target tissue for ISIs because 
it is a naturally constrained geometry, and the network of trabecular bone would require a liquid 
injection for interpenetration of a scaffold. However, ISIs would require modification of the 
microarchitectural and material properties in order to be considered as drug delivery scaffolds for 
these intraosseous applications.  
2.4. Significance and Objectives 
 The PLGA ISIs are approved for clinical use in their simplest form, with a single drug freely 
mixed into the PLGA phase, and most research has focused on modulating release kinetics by 
varying PLGA and solvent concentration or chemistry. However, incorporating micro- and 
nanoparticle additives into the PLGA matrix may be able to influence drug release and mechanical 
properties without modifying the polymer or solvent. Micro- and nanoparticle additives have 
been incorporated into pre-formed implants to produce composite scaffolds with a wide range of 
physical and chemical properties, and this approach allows a material as simple as PLGA to be 
used as a drug delivery scaffold for soft tissue or orthopedic applications. It is important to note 
that ISIs are currently considered simply as injectable drug depots, rather than functional scaffolds 
that can aid in tissue regeneration, because there is very little control over the microstructure or 
mechanical properties as they solidify. Conceivably, composite ISIs can be considered as drug-
delivering scaffolds instead of simply as injectable drug depots. The objective of this research is 
to develop a modular platform that is easily adapted to different drugs and tissues by varying 
particulate additives. This research is divided into three separate aims, of which the first two focus 
on development of a composite PLGA ISI for orthopedic applications, and the last of which seeks 
to improve the properties of PLGA ISIs used in dental applications. 
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2.5. Specific Aims 
Aim 1: To characterize the drug release and microarchitectural properties of novel orthopedic ISI. 
These composite PBAE-PLGA-HA ISIs were created by admixing drug-loaded PBAE hydrogel 
microparticles and HA microparticles into a PLGA solution prior to injection. The potential of PBAE 
and HA microparticles to modulate release of simvastatin and clodronate was investigated. 
Aim 2: To demonstrate the feasibility of the orthopedic ISI from Aim 1 as a mechanically 
supportive scaffold. The HA content and particle size were varied with the objective of creating a 
material that is mechanically similar to trabecular bone. Injectability was quantified to ensure that 
the injectable mixture could be handled in a clinical setting, and as a proof of concept, the mixture 
was injected ex vivo into intact porcine femoral heads. 
Aim 3: To develop a composite PBAE-PLGA ISI that is suitable for soft tissue applications such as 
periodontal drug delivery in gingival tissue. PBAE content was increased compared to Aims 1 and 
2, HA not used, and two different molecular weights of PLGA were considered. Co-delivery of 
doxycycline and simvastatin was investigated. The development of porosity and the preservation 
of microstructure and mechanical resilience throughout degradation was investigated, and the 
goal of these experiments was to demonstrate the potential for these ISIs as tissue engineering 
scaffolds for future studies. 
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Chapter 3 Improved small molecule drug release from in situ forming poly(lactic-co-glycolic 
acid) scaffolds incorporating poly(β-amino ester) and hydroxyapatite microparticles   
This chapter reproduced from a published manuscript, “Fisher, P.D., P. Palomino, T.A. Milbrandt, 
J.Z. Hilt, and D.A. Puleo, Improved small molecule drug release from in situ forming poly(lactic-
co-glycolic acid) scaffolds incorporating poly(beta-amino ester) and hydroxyapatite 
microparticles. Journal of Biomaterials Science. Polymer Edition, 2014. 25(11): p. 1174-93.” 
3.1. Introduction 
Controlled drug delivery systems offer a variety of potential advantages over traditional 
routes of administration, such as oral dosages and intravenous or subcutaneous injection of drug 
solutions, due to their spatial and temporal control over drug release [191]. Traditional dosage 
forms result in systemic circulation of drug, and the oral route is also subject to first-pass 
metabolism [192]. Injections introduce a bolus of drug at high concentrations, and long-term 
treatment requires repeated dosing, resulting in pulsatile concentration profiles [193]. 
Implantable drug-loaded scaffolds can be placed at the treatment site to minimize systemic 
exposure and can be designed to control release kinetics by varying the chemical and physical 
nature of the carrier [193, 194]. These systems, however, generally require a surgical procedure 
to implant the device, and in the case of a non-degrading material, require a removal surgery. As 
a result, significant effort in the drug delivery field has focused on injectable, biodegradable drug 
carriers, such as in situ gelling, polymerizing, or precipitating systems [195, 196]. A space-filling 
scaffold capable of forming into a biodegradable solid at the treatment site is an appealing option 
because it can penetrate a tissue network to deliver drugs at a fixed location with minimal 
invasiveness and no removal surgery.  
Poly(lactic-co-glycolic acid) (PLGA) is an attractive material for an in situ forming delivery 
system because it is already present in FDA-approved injectable products (Atridox® and Atrigel® 
systems), it degrades hydrolytically, and its physical properties can be controlled by varying the 
lactide:glycolide ratio, molecular weight, and end species [197]. PLGA is dissolved in a water-
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miscible solvent and mixed with a pharmaceutical agent prior to injection to form a drug 
suspension or solution. The resulting mixture is injected into the treatment site, where it 
precipitates into a solid and gradually releases the drug [198]. These systems have been 
investigated for protein release [146, 199] as well as small molecule drugs [200], and have 
demonstrated biocompatibility [147].  
Typically, injectable PLGA systems have a large initial burst release followed by sustained 
release over a period of hours to weeks [195]. The magnitude of this burst release as well as 
precipitation rate are both governed by the rate of solvent exchange [137, 139]. Therefore, 
systems with lower initial burst tend to undergo slower solidification due to gradual solvent 
exchange, while rapid precipitation corresponds to rapid solvent exchange and correspondingly 
large burst. Release kinetics following the burst are primarily diffusive until degradation of the 
polymer matrix becomes a contributing factor [139]. The burst can be reduced by increasing 
polymer content of the solution, increasing polymer molecular weight, or changing to a less 
water-miscible solvent [138, 195, 201]. However, increasing polymer content increases the 
viscosity of the solution, slows precipitation, and leads to the formation of a low-porosity “skin” 
around the scaffold [139, 202]. Increasing polymer molecular weight and/or hydrophobicity 
increases degradation time [138], and choosing a less water-miscible solvent dramatically slows 
precipitation [137, 201].  
Incorporating drug-loaded microparticles into an injectable PLGA system may provide a 
secondary means of controlling release kinetics. This concept has been previously investigated by 
mixing PLGA microspheres containing plasmid DNA into the PLGA solution prior to injection [203].  
PLGA microspheres will dissolve in the organic solvents used in the system, however, which 
confers a time constraint on the mixing process and may be unsuitable for small molecule drugs 
that can easily escape from partially dissolved microspheres. By instead utilizing crosslinked 
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microparticles that will not dissolve in NMP but are still hydrolytically degradable, the utility of 
the in situ forming PLGA system may be greatly expanded. Poly(β-amino ester) (PBAE) hydrogels 
are formed via step growth polymerization of a diacrylate and an amine followed by free radical 
crosslinking, and degradation time can be modified by changing the monomers to influence 
crosslink density and hydrophilicity [69]. Recently, PBAE microparticle and nanoparticle systems 
have been investigated for their drug delivery potential [75, 204, 205]. Incorporation of drug-
loaded PBAE microparticles into an injectable PLGA system has the potential advantage of 
controlling and prolonging drug delivery while reducing initial burst. 
Intraosseous injection in particular is a suitable application for an in situ forming system 
due to the interconnected porous network of the trabecular bone that makes placement of pre-
formed scaffolds difficult and removal surgery impossible. Injectable PLGA systems can 
theoretically accommodate filler particles such as hydroxyapatite (HA) to influence 
microarchitecture, mechanical properties, or osteoconductivity. N-methyl-2-pyrrolidone (NMP), 
currently used in the FDA-approved Atrigel and Atridox delivery systems, is highly water-miscible 
and provides rapid solidification. Additionally, NMP has been shown to promote bone 
morphogenetic protein 2 (BMP-2) dependent alkaline phosphatase activity as well as reduce 
osteoclast activity [206, 207]. Bisphosphonates, such as clodronate, are used to prevent bone 
resorption via osteoclast apoptosis or inactivation [189]. Simvastatin is a drug that is primarily 
used for its inhibition of 3-hydroxy-3-methylglutaryl coenzyme A to treat high cholesterol, but it 
has recently been investigated for osteogenic applications due to numerous studies reporting that 
simvastatin promotes bone formation via BMP-2 upregulation [190, 208].  
Clodronate and simvastatin are both small molecule drugs, and therefore they are prone 
to rapid release and high burst in a traditional in situ forming PLGA system. It was hypothesized 
that an in situ forming PLGA system containing drug-loaded PBAE microparticles and HA filler 
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would provide superior simvastatin and clodronate release kinetics compared to existing systems 
using freely mixed drugs. 
3.2. Materials and Methods 
3.2.1. Materials 
Poly(lactic-co-glycolic acid) (PLGA; 50:50 L:G, acid terminated, inherent viscosity 0.55-
0.75 dL/g) was purchased from DURECT, Inc. (Birmingham, AL, USA). Simvastatin was purchased 
from Haorui Pharma-Chem (Edison, NJ, USA). Clodronate, hydroxyapatite, 2,2-dimethoxy-2-
phenylacetophenone (DMPA), and N-methyl-2-pyrrolidone (NMP) were obtained from Sigma-
Aldrich (St. Louis, MO, USA).  
3.2.2. PBAE polymer synthesis 
PBAE macromer was synthesized by reacting diethylene glycol diacrylate and 
isobutylamine at a 1.2:1 diacrylate:amine molar ratio at 85oC for 16 hours. Macromer was stored 
in an opaque vial under refrigeration until use. To create crosslinked hydrogels from macromer, 
1 wt/wt% DMPA initiator dissolved in 50 wt/wt% ethanol was vortexed with macromer. The 
mixture was then pipetted between two glass plates with Teflon spacers, sealed and clamped, 
and then exposed to a UV flood source with an intensity of 12 mW/cm2 for 5 minutes to form a 
crosslinked hydrogel slab. These PBAE hydrogel slabs were washed overnight in ethanol to 
remove unreacted monomer and initiator, and then stored in a desiccator to remain dry until use. 
3.2.3. PBAE particle formation and drug loading 
PBAE microparticles were formed by grinding dry PBAE slabs with a mortar and pestle, 
with HA added during the grinding process to coat particles and prevent aggregation. HA content 
was preliminarily tested at 66 w/w % and 75 w/w % weight ratios, and 75% (50 v/v %) was chosen 
due to ease of particle fabrication. PBAE particles were sieved to less than 250 μm, and larger 
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particles were re-ground until all material was collected through the sieve. A Zeiss Evo MA 10 
scanning electron microscope (SEM) (Carl Zeiss, Thornwood, NY) at 4 kV accelerating voltage was 
used to visualize particle morphology, and a Quantax energy-dispersive x-ray spectroscopy (EDS) 
detector was used for elemental analysis. A series of 10 microscope images of HA and PBAE 
particles were analyzed using freely available ImageJ software to calculate mean particle size. 
Simvastatin was either loaded into PBAE slabs prior to particle formation (pre-loaded) or 
loaded directly into PBAE microparticles (post-loaded), and each method was assessed for loading 
efficiency as well as the percentage of drug that was weakly bound to particle surface. Figure 3.1A 
graphically represents the processing method for creating PBAE microparticles, as well as the 
differences between pre- and post-loaded particles. Post-loaded particles were prepared by 
dissolving simvastatin in ethanol at a concentration of 100 mg/mL and pipetting drug solution 
over particles at a ratio of 2 µL per mg of particles. This ratio allowed particles to swell without 
excess solution remaining, and expected drug loads were calculated under the assumption that 
all drug solution was imbibed by the microparticles. Particles were lyophilized overnight, briefly 
re-ground and sieved to break up aggregates, and stored in a vacuum chamber with desiccant.  
Pre-loaded microparticles were prepared by immersing PBAE slabs in simvastatin solution, 
allowing the hydrogel to swell for 24 hours, and then removing the hydrogel and lyophilizing 
overnight to evaporate ethanol. Drug-loaded PBAE slabs were ground with 75 wt% HA into 
particles and stored in a vacuum chamber with desiccant. Predicted values for drug loading using 
the pre-loading method were obtained by calculating swelling of PBAE in solution based on mass 
increase and assuming drug was homogeneously present in swollen hydrogels as well as 
surrounding solution. The density and concentration of the drug solution was then used to 
calculate expected drug loading based on mass change of the PBAE samples. Clodronate was 
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loaded into separate batches of microparticles using an identical pre-loading technique with a 50 
mg/mL clodronate solution in deionized water.  
3.2.4. Measurement of drug loading into PBAE  
Simvastatin loading into PBAE microparticles was measured by immersing drug-loaded 
particles in ethanol, vortexing, and allowing the particles to swell for 24 hours. The mixtures 
containing ethanol and swollen PBAE microparticles were then centrifuged, and supernatants 
were analyzed using HPLC to detect simvastatin as described in 2.7 Measurement of drug 
concentrations.  Clodronate loading was measured with an identical technique using 50% ethanol, 
and was detected by absorbance as described below. A mass balance indicated that all drug was 
successfully removed from the particles during 24 hours of immersion in ethanol for simvastatin 
or 50% ethanol solutions for clodronate, and subsequent immersions extracted no additional 
drug. Loading efficiency was defined as the ratio of the total mass of drug loaded into the particles 
to the initial mass of drug exposed to the particles.   
In addition to loading efficiency, the percentage of drug present on the surface of particles 
was determined by washing drug-loaded particles with 5 mL ethanol over a filter to remove 
loosely surface-bound simvastatin or with 5 mL deionized water to remove loosely surface-bound 
clodronate. The remainder of drug present in the bulk of the microparticles was extracted by 
immersing particles for 24 hours in ethanol for simvastatin or 50% ethanol for clodronate. Drug 
detected in the initial wash was deemed loosely bound to the surface of particles, while drug 
detected after the 24 hour soak was determined to be imbibed into the bulk of the particles. 
3.2.5. Formation of injectable scaffold system 
PLGA was added to NMP and stirred overnight until fully dissolved to create a 20 wt/wt% 
PLGA solution. Simvastatin-loaded PBAE microparticles pre-loaded using 100 mg/mL simvastatin 
were added at 5 wt% and mixed homogeneously prior to injection. HA was also mixed 
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homogeneously prior to injection to bring the final mixture to 30 wt% HA. Clodronate-loaded 
PBAE microparticles pre-loaded with 50 mg/mL clodronate were added using an identical 
technique. Samples without microparticles were prepared by freely mixing 1 wt% simvastatin or 
clodronate into 20% PLGA solution to simulate a traditional in situ forming PLGA system. Figure 
3.1B illustrates the differences between the proposed system and a traditional injectable system. 
Simvastatin and clodronate were measured as described in 3.2.7. Measurement of drug 
concentrations.  
 
Figure 3.1. PBAE microparticle and injectable scaffold fabrication process. A) Technique for 
formation of PBAE hydrogels and processing them into drug-containing pre- or post-loaded 
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microparticles. B) Comparison of a traditional injectable PLGA system (right) to the proposed 
system (left). 
3.2.6. In vitro drug release  
The scaffold mixture was injected dropwise through a 16 gauge, blunt-tipped dispensing 
needle into PBS at 5% wt/vol. Upon contacting PBS, surface PLGA immediately began to 
precipitate, forming semi-spherical scaffolds approximately 3 mm in diameter that sank to the 
bottom of the vial. Samples were kept in an incubator at 37°C on a plate shaker for the duration 
of the study. Supernatant was collected and replaced at each time point, and these samples were 
preserved at 4oC until analysis. Clodronate release was measured for three loading conditions: 
freely mixed clodronate without HA filler, freely mixed clodronate with HA filler, and clodronate 
pre-loaded into PBAE microparticles with HA filler. Because PBAE microparticles were fabricated 
with HA as a dispersing agent, drug release from loaded particles was not investigated without 
HA filler. Simvastatin release was measured for three loading conditions: freely mixed simvastatin 
without HA filler, freely mixed simvastatin with HA filler, and simvastatin pre-loaded into PBAE 
microparticles with HA filler. 
3.2.7. Measurement of drug concentrations 
Simvastatin was measured on a Hitachi Primaide HPLC system equipped with a C18 
column using a mobile phase composed of 70% acetonitrile and 30% water with 0.1% 
trifluoroacetic acid at a flow rate of 1 mL/min, and peaks were observed at 240nm. Clodronate 
from collected supernatants were measured using a Powerwave HT (Biotek; Winooski, VT, USA). 
In vitro release supernatant was pipetted into a UV-grade 96-well plate (Greiner Bio-One, 
Frickenhausen, Germany), and baseline absorbance was measured at 240 nm. On its own, 
clodronate does not exhibit a distinct absorption peak, so concentration was measured by mixing 
32 
 
supernatant with a solution of 1.5 mM copper sulfate and 1.5 mM nitric acid at pH 2 to form a 
clodronate-copper complex that exhibits absorption at 240 nm [209]. A pilot experiment 
confirmed that HA did not significantly interfere with clodronate readings in the working range.  
3.2.8. Characterization of release kinetics 
Drug release from polymeric systems is often analyzed using an adaptation of the Higuchi 
model by Peppas et al., widely known as the power law, to characterize release kinetics [210]: 
𝑀𝑡
𝑀∞
= 𝑘𝑡𝑛            (3.1) 
Here, Mt is the mass of drug at time t, M is the total mass of drug in the system, 
𝑀𝑡
𝑀∞
 represents 
fractional release of drug at time 𝑡, 𝑘 is a constant encompassing scaffold and drug properties, 
and 𝑛 is the release exponent used to characterize drug release. In the case of the spherical 
geometry (consistent with scaffolds formed via dropwise injection), 𝑛 = 0.43 corresponds to pure 
Fickian diffusion, 𝑛 =0.85 corresponds to pure case II (polymer relaxation-based) transport, and 
values in between are combinations of the two, termed anomalous transport [210]. Plots of 
log
𝑀𝑡
𝑀∞
 versus log 𝑡 were used to determine 𝑛 for each drug. The power law is applicable when 
𝑀𝑡
𝑀∞
< 0.6, so release data were truncated to below 60% cumulative release when calculating 𝑛.   
3.2.9. Mass loss and degradation 
The injectable scaffold system was prepared as described previously, using unloaded 
microparticles. Non-destructive degradation analysis was performed on hydrated scaffolds in 
order to observe the mass change of wet samples. Scaffolds were injected dropwise into PBS and 
incubated at 37oC on a shaker for 80 days. Initial injected mass was recorded for each scaffold. At 
intervals, scaffolds were removed from PBS, gently blotted dry, and weighed. Destructive analysis 
of dried samples was used to analyze scaffold dry mass change. Scaffolds were injected dropwise 
into PBS and incubated at 37ºC on a plate shaker until analysis. At each time point, scaffolds were 
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lyophilized for 24 hours, and dry weight was measured. Lyophilized scaffolds were also scanned 
using a Scanco MicroCT 40 (Scanco Medical, Switzerland) at 55 kV and 145 mA with 6 μm voxel 
size.  The built in bone trabecular morphometry tool was used to create 3D reconstructions to 
visualize microarchitecture and quantify porosity and pore size at various time points during the 
degradation process. 
3.2.10. Statistical analysis 
 All data are presented as mean ± standard deviation. Release data were analyzed in JMP 
10 software, using one-way analysis of variance (ANOVA) to determine differences between 
release curves followed by Tukey-Kramer mean comparison tests as necessary. Comparisons 
between individual pairs of samples for loading efficiencies were performed using a student’s 
two-tailed t-test. Differences were considered significant for p < 0.05.   
3.3. Results 
3.3.1. Drug loading into PBAE particles. 
 Drug loading into PBAE increased linearly with drug solution concentration for simvastatin 
(Figure 3.2A) and clodronate (Figure 3.2B and 3.2C). Clodronate became insoluble at 20 mg/mL in 
50% ethanol, while the drug remained soluble through 100 mg/mL in DI water. At 100 mg/mL 
clodronate, however, it was observed that hydrogel would swell to a greater degree and fracture 
upon handling, leading to high variability between samples (Figure 3.2C), so 50 mg/mL clodronate 
in DI water was used for future experiments. Simvastatin was loaded into gels or particles using a 
100 mg/mL solution in 100% ethanol.  
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Figure 3.2. Drug loading into PBAE hydrogel.  A) Simvastatin loading after soaking in 100% ethanol 
solutions for 24 hours. B) Loading after soaking in 50% ethanol clodronate solution for 24 hours. 
C) Loading after immersion in aqueous clodronate solution for 24 hours.  Data are mean ± 
standard deviation (n=3). 
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HA possessed a mean particle diameter of 10 μm, while the PBAE particles produced by 
grinding PBAE hydrogels together with HA had a mean diameter of 68 μm. PBAE microparticles 
exhibited a composite structure consisting of spherical particles consistent with HA sizes 
embedded in an amorphous material consistent with the hydrogel nature of PBAE (Figure 3.3A). 
The spherical HA particles exhibited a rough, granular surface morphology, compared to the 
smooth PBAE component. EDS elemental mapping showed calcium and phosphorous localized to 
the spherical particles (Figure 3.3B). Point analysis of presumed HA and PBAE regions indicated 
higher calcium and phosphorous levels in spherical HA particles, and higher carbon and oxygen 
content in the PBAE region (Figure 3.3C).  When these microparticles were immersed in a mixture 
of 20% PLGA solution in NMP with 30 wt% HA added to simulate pre-injection conditions, they 
underwent a 47% mass increase due to swelling (Figure 3.3D), with a 28% increase occurring 
within 5 minutes. 
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Figure 3.3. Morphology, composition, and swelling of PBAE microparticles.  A) SEM image of a 
PBAE microparticle, with EDS performed on the highlighted portion. B) Top left: Region chosen 
from (A) for EDS analysis, with arrows indicating points of spectral analysis performed in (C). 
Bottom left: Composite overlay of calcium and phosphorous on that region. Top right: EDS 
detection of calcium. Bottom right: EDS detection of phosphorous. B). C) EDS spectra of an HA 
particle (blue) and PBAE (red).  D) PBAE swelling kinetics expressed as a percentage of mass 
increase in injection mixture (30 wt% HA mixed into 20% PLGA solution). Data are mean ± 
standard deviation (n=3). 
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Efficiency of incorporating simvastatin into post-loaded particles ranged from 52% to 77% 
(Figure 3.4B), and efficiency ranged from 89% to 96% in pre-loaded particles (Figure 3.4D).  A 
surface wash indicated that between 69% and 77% of simvastatin was loosely surface-bound to 
post-loaded particles, with no differences between simvastatin concentrations (Figure 3.4C). 
Using the pre-loading technique, a significantly lower amount (p < .05), between 46% and 51% of 
simvastatin, was loosely surface-bound, again with no concentration dependence (Figure 3.4A). 
Pre-loaded clodronate yielded particles with 74% to 86% of drug loosely surface-bound (Figure 
3.4E). Clodronate loading efficiency ranged from 91% to 97% at concentrations up to 50 mg/mL, 
and dropped to 59% at 100 mg/mL (Figure 3.4F). 
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Figure 3.4. Surface vs. bulk loading in microparticles: A) simvastatin post-loaded, C) simvastatin 
pre-loaded, and E) clodronate pre-loaded. Loading efficiency: B) post-loaded simvastatin, D) pre-
loaded simvastatin, and F) pre-loaded clodronate. Data are mean ± standard deviation (n=3).   
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3.3.2. In vitro release 
 Freely mixed simvastatin was 81% released within 1 day and 95% released within 10 days, 
with no difference between scaffolds prepared with or without HA (Figure 3.5A). In both cases, 
there was a gradual decrease in release rate as fractional release (Mt/M∞) reached 100%. Pre-
loaded simvastatin microparticles mixed into the system reduced the 1 day burst to 39% (p<0.05), 
followed by sustained release of 1.3%/day for 30 days. The sustained release from day 1 through 
day 30 was roughly linear, with no appreciable decrease in rate until completion of drug release.  
Freely mixed clodronate prepared without HA exhibited a 49% burst within one day of 
release, while both freely mixed and pre-loaded clodronate prepared with HA produced 32% burst 
(p<0.05) (Figure 3.5B). Freely mixed clodronate without HA gradually released at a rate of 
0.6%/day through day 19, while clodronate mixed with HA or pre-loaded into microparticles 
released at 1.3%/day through day 19. By day 20, there was no difference in total clodronate 
release between each curve. All clodronate release curves showed a distinct increase in release 
rate to 3%/day at day 20 that continued through day 31, after which nearly all drug was released.   
To characterize release kinetics, plots of log
𝑀𝑡
𝑀∞
 vs log 𝑡 were used to calculate 𝑛 for pre-
loaded simvastatin and clodronate through the first day of release. After the first day, release 
rates tended to be linear and were therefore expressed as a daily release rate. For initial release 
during the burst, simvastatin and clodronate release exhibited 𝑛 = 0.47 and 𝑛 = 0.49, 
respectively.  
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Figure 3.5. Cumulative release profiles.  A) Release of simvastatin loaded freely into the PLGA 
solution with (∆) or without HA (○), or loaded into PBAE (□) (n=3). B) Release of clodronate 
freely loaded into PLGA solution with (∆) or without HA (○), or loaded into PBAE microparticles 
(□) (n=4). Data are mean ± standard deviation. 
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3.3.3. Mass loss and degradation 
 Lyophilized scaffolds exhibited an initial mass loss of 50% in the first hour, followed by an 
additional gradual decrease of 5% over the first day (Figure 3.6A). Mass fraction remained 
unchanged at approximately 45% for 15 days, followed by a linear decrease in mass at a rate of 
0.2%/day until day 50. Mass fraction did not change significantly after day 50, ranging from 25% 
to 29% through day 80. Lyophilized samples collected at day 40 and beyond were primarily 
powder that crumbled upon handling. 
Non-destructive mass change of wet scaffolds showed an initial 12% decrease in mass 
over the first day, followed by a linear increase of 1.4%/day over the next 14 days (Figure 3.6B). 
At day 15, mass fraction became more variable as some samples began to decrease in mass, while 
others swelled through day 30. Linear mass loss was observed from day 30 through day 55, when 
the remaining mass fraction stabilized at 20% until day 80.  
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Figure 3.6. Degradation of in situ forming PLGA scaffolds.  A) Destructive mass loss showing dry 
mass change expressed as a fraction of pre-injection mass (n=3). B) Non-destructive mass loss 
showing total hydrated scaffold mass change, expressed as a fraction of pre-injection volume 
(n=5). Data are mean ± standard deviation 
Qualitative assessment of microCT cutplanes roughly bisecting samples revealed a 
uniformly porous microstructure through day 10 (Figure 3.7). By day 15, denser regions had 
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developed in the middle and at the edges of scaffolds. By day 20, large macropores were present 
in the core of the scaffolds. At day 25, scaffold cores appeared more uniformly porous, and the 
denser regions near the edges of scaffolds had become more porous. The dense regions appeared 
to migrate towards one side of the scaffold by day 30, and by day 35, scaffolds had significantly 
decreased in size, leaving behind a uniformly porous pellet. After day 35, scaffolds were too fragile 
to handle, and a representative sample of residual material collected at day 40 was nonporous. 
MicroCT morphometry revealed an increase in porosity from 31% through day 20 to 47% by day 
30, followed by a return to 30% at day 35 (Figure 3.8A). Average pore size ranged from 40 to 100 
µm, except for samples at day 25, which had average pore size of 231 µm (Figure 3.8B).  
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Figure 3.7. Representative microCT cut-plane images of lyophilized scaffolds showing internal 
microarchitecture throughout the degradation process. Scale bars are 1 mm. 
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Figure 3.8. Morphometric parameters during degradation. A) Porosity and B) average pore size 
measured by microCT evaluation of samples through 35 days. 
3.4. Discussion 
3.4.1. Drug loading 
PBAE microparticles were successfully formed by co-grinding PBAE hydrogels with HA, 
forming individual PBAE particles coated with multiple, smaller HA particles. Elemental analysis 
confirmed that the smaller, spherical coating consisted of HA, and the underlying particles were 
hydrogel.  Simvastatin pre-loaded into PBAE hydrogels showed both higher loading efficiency and 
bulk imbibition of drug, which are favorable conditions to prolong drug release relative to freely 
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mixed drug. Swelling data were found to be an accurate predictor of drug loading into gels at 
various concentrations, consistent with previous drug loading results with hydrogels [211]. It was 
determined that processing of particles does not appreciably affect simvastatin loading efficiency 
using the pre-loading technique while still providing favorable imbibition ratios of surface to bulk 
drug. A decrease in loading efficiency as well as a higher percentage of simvastatin present loosely 
bound to the surface of particles using a post-loading technique may be attributable to the free 
HA powder used to coat the PBAE particles absorbing a percentage of drug solution, preventing 
its complete penetration into the hydrogel and resulting in a majority of drug sequestered outside 
the hydrogel microparticles. The high levels of surface drug seen for clodronate pre-loading may 
be due to the fact that the PBAE used in these experiments swells to a significantly larger degree 
in ethanol than in water (data not shown), allowing less penetration of drug into the bulk of the 
gels. Additionally, clodronate was more favorably loaded into PBAEs in aqueous solutions rather 
than 50% ethanol solutions because its solubility was limited. The swelling kinetics of PBAEs in the 
injection mixture (30 wt% HA in 20% PLGA solution) suggest that particles swell appreciably due 
to NMP exposure prior to injection, but the magnitude of swelling is negligible compared to the 
amount observed in pure NMP (47% at equilibrium vs. 470% in pure NMP). This difference is due 
to the presence of PLGA, which dissolves readily in NMP [146] and prevents hydrogels from fully 
swelling as they would in pure NMP. Additionally, the particles may be immersed in PLGA solution 
for only a matter of minutes before injection, so realistically, particles may swell by only 23% if 
the system is injected 5 minutes after addition of microparticles to the PLGA solution. 
3.4.2. Simvastatin and clodronate release 
 Simvastatin release was strongly affected by its loading state. A comparison of release 
kinetics between injectable systems loaded with freely mixed simvastatin and simvastatin-loaded 
PBAE microparticles indicated that burst release can be significantly reduced and duration of 
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release can be significantly extended by loading simvastatin into PBAE microparticles. Because 
simvastatin is soluble in NMP, freely mixed drug presumably was dissolved in NMP and the 
majority of it exited into the aqueous phase during the solvent exchange process, resulting in a 
large burst release. The residual 20% of simvastatin was released in a sustained manner over the 
next 10 days, similar to previous work on such systems using freely mixed drug [212, 213]. PBAE 
microparticles experience some swelling in the NMP-PLGA solution during the mixing stage prior 
to injection, but burst is attenuated for pre-loaded PBAE microparticles. The 39% burst release 
through day 1 using pre-loaded particles may be attributable to loosely surface-bound simvastatin 
that was likely dissolved by NMP and released during solvent exchange, similarly to freely-mixed 
simvastatin. Because simvastatin was loaded into PBAE with high efficiency, the release kinetics 
are likely a combination of the swelling, degradation, and diffusion of drug through the PBAE 
material as well as the PLGA phase.   
 Clodronate release appeared to be unaffected by loading state of the drug in PBAE 
microparticles, but it was instead dependent on the presence of HA in the injection mixture. This 
can be attributed to the formation of a complex between the bisphosphonate drug and 
hydroxyapatite, specifically between the two phosphonate groups of clodronate and the divalent 
calcium cations present in HA crystals [214]. Freely mixed clodronate without HA filler was 49% 
released within 1 day, compared to 32% for both compositions with HA. Because clodronate is 
insoluble in NMP, this initial burst is likely due to free clodronate suspended in the PLGA solution 
being dissolved by water during solvent exchange. The increase in release rate observed around 
day 20 corresponded to the maximum swelling state of scaffolds, indicating that scaffolds had 
begun to appreciably degrade and more water could enter the system to promote more rapid 
clodronate dissolution. Samples prepared with HA had a lower burst and higher release rate 
between days 1 and 20 due to the clodronate being initially retained in the system by 
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complexation, after which the drug was released diffusively from the solidified system. 
Clodronate release kinetics are consistent with the classic 3-stage release profiles observed in 
rapidly-precipitating systems, in which an initial burst is followed by slow diffusion, and then a 
more rapid swelling- or degradation-mediated release occurs [215]. Interestingly, the slow 
diffusion stage was accelerated by the addition of HA, likely because the larger amount of drug 
retained in the scaffold provided a higher concentration gradient to drive diffusion.  
The rapid precipitation implied by the initial burst of clodronate and simvastatin as well 
as the early mass loss is indicative of rapid NMP exchange, which demonstrates the potential of 
the system for rapid solidification.  Fast precipitation is favorable for quick delivery of NMP for an 
initial osteogenic stimulus, and rapid formation of a solid drug delivery depot may have 
advantages over gradually precipitating systems with persistent gel or liquid cores for days or 
weeks after injection due to NMP retention [213]. Specifically, this has implications for 
intraosseous injection, where the system can completely precipitate within days while continuing 
to release drug over a period of weeks to months. In systems with freely suspended or dissolved 
drug, precipitation rate strongly influences burst release [137, 216], and the addition of drug-
loaded PBAE microparticles can allow for prolonged release and decreased burst without 
prolonging precipitation of the system. The rapid precipitation may also allow filler particles, such 
as hydroxyapatite, to provide mechanical support in future iterations of the system.  After the 
initial burst, pre-loaded simvastatin exhibited prolonged delivery over the entire 30 day period. 
The lack of change in simvastatin release kinetics upon addition of 30 wt% HA was expected, 
because HA should not appreciably interact with statins, which lack the phosphonate groups that 
provide binding sites for the calcium in HA. The successful demonstration of sustained release of 
both hydrophilic and hydrophobic small molecule drugs with reduced burst from this system 
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shows promise for new applications of in situ forming PLGA systems where rapid precipitation is 
required.   
By fitting the power law to initial drug release, the release exponent n can be used to 
classify the mechanism of drug release from the system. For simvastatin, n of 0.47 indicates 
primarily Fickian diffusion based on the standard n values for a spherical scaffold of n=0.43 for 
pure Fickian diffusion and n=0.85 for pure Case II transport. The slightly higher release exponent 
compared to the pure Fickian value can be attributed to several factors, including the swelling of 
the PBAE hydrogel microparticles and minor swelling of the surrounding PLGA matrix. Similarly, n 
of 0.49 for clodronate corresponds to primarily Fickian diffusion as well. Both clodronate and 
simvastatin are therefore released via diffusive mechanisms prior to their sustained release, 
which follows a more linear trend. This data supports the idea that the burst was composed of a 
fraction of the loaded drug dissolved or suspended in NMP, and the rapid solvent exchange was 
likely responsible for the initial release. The sustained release was likely a combination of 
diffusion, erosion, and swelling-based mechanisms, and the superposition of these mechanisms 
produces release curves that are most simply expressed in daily release rates. Because simvastatin 
is almost insoluble in water but highly soluble in NMP, the larger burst compared to clodronate is 
unsurprising, as dissolved simvastatin may be transported out of the scaffold during the solvent 
exchange phase. Future iterations of the system may be able to further reduce burst by reducing 
access of drug to the NMP phase to limit the initial diffusive component of the system. 
3.4.3. Degradation and mass loss 
PLGA is a bulk-eroding material that degrades via hydrolysis of ester bonds, resulting in a 
progressive decrease in molecular weight until monomeric or oligomeric species of sufficiently 
low molecular weight are generated and cleared when molecular weight drops to approximately 
1.5 kDa  [217, 218]. The in situ forming scaffold has the additional property of a rapid precipitation 
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event upon injection, and due to the high aqueous miscibility of NMP, a rapid initial dry mass loss 
was observed within the first hour following injection as NMP entered the aqueous phase and the 
highly hydrophobic PLGA precipitated. By 24 hours, 46% dry mass remained, corresponding to the 
loss of the majority of the NMP content that composed 54 wt% of the system. The subsequent 
lack of dry mass change suggests that hydrolytic degradation was unable to produce small enough 
molecular weight species to be cleared into the surrounding aqueous environment until day 15. 
After day 15, the linear decrease in dry mass corresponded to clearance of degradation 
byproducts until all PLGA was removed from the system. The remaining 29% dry mass can be 
attributed to remaining HA content that composed 30% of the original mass. For wet scaffolds, 
the initial 12% decrease in wet mass throughout the first day of degradation supports the 
replacement of NMP with water due to precipitation of PLGA. The 20% increase in wet mass over 
the following 14 days indicates swelling of the PLGA matrix. Following this brief swelling, 
individual sample behavior diverged as swelling reached a maximum between 110-120% between 
days 20-30. The linear decrease in mass was delayed compared to dry samples because the small 
losses in polymer degradation byproducts were offset by increased water content as the system 
swelled. The lack of mass change beyond day 55 was consistent with the complete clearance of 
PLGA observed in dry mass studies, and the lower mass fraction remaining (20% compared to 
29%) was likely due to repeated handling of samples during nondestructive measurements 
resulting in small amounts of HA being resuspended and removed with supernatant at each time 
point.  
Based on microCT images, it was evident that scaffold microarchitecture underwent 
dramatic changes throughout the degradation process. The first indicator of change was the 
development of denser regions in the core and near the edges of scaffold by day 15, which may 
be attributable to the cessation of NMP release and the hydrophobicity of PLGA causing solid 
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regions to condense together. At day 20, the highest pore size was observed as large, closed 
macropores. This phenomenon corresponds to the scaffolds at their maximum swelling state 
based on wet mass, and was accompanied by further densification of the core and edge regions. 
At day 25, the core remained dense, but macropores were no longer evident, and the edges of 
scaffolds were less dense and more porous, which is consistent with reports of PLGA of this 
molecular weight beginning to lose mass to clearance after 3 weeks [218]. At day 30, it is possible 
that enough polymer had been lost to allow mobility of HA content through the PLGA, which 
settled at the bottom of scaffolds during incubation. By day 35, scaffold density and pore 
distribution appeared more uniform, and scaffolds were noticeably smaller in size due to further 
degradation of the highly porous regions seen at day 30.  
3.4.4. Advantages of the system 
In situ forming PLGA systems have been popularized due to their ease of use and unique 
ability to solidify at the point of injection, forming a drug delivery depot in the tissue of interest. 
However, because drug release from these systems is highly dependent on solvent exchange and 
polymer chemistry [137], release of multiple agents with unique release profiles is challenging. 
Additionally, low molecular weight drugs tend to exit during the solvent exchange, resulting in 
high initial burst [139]. Multiple drug release platforms for small molecule drugs, therefore, tend 
to be pre-formed scaffolds or injectable suspensions of micro- or nanoparticles [219-222]. The 
addition of PBAE microparticles to the in situ forming PLGA system combines the ease of use of 
injectable systems, the controlled release of microparticle systems, and the spatial control of solid 
scaffolds. Even in a rapidly-solidifying system, PBAE microparticles are capable of prolonging 
release of both hydrophilic and hydrophobic drugs over a 30 day period with significantly less 
burst than traditional injectable PLGA systems using freely mixed drug.  
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3.5. Conclusions 
An in situ hardening, PLGA-based system offers a unique drug delivery platform due to its 
injectability and space-filling properties, and the addition of drug-loaded microparticles 
introduces the possibility for tunable release profiles for multiple pharmaceutical agents. In 
addition to the potential for multiple release profiles, the addition of drug-loaded PBAE 
microparticles enables the sustained release of water-soluble, small molecule drugs, such as 
clodronate, as well as lipophilic drugs, such as simvastatin, independent of PLGA precipitation. 
The biodegradability of the system makes this a favorable candidate for applications where a 
secondary surgery to remove the depleted scaffold is undesirable or impossible. Release kinetics 
can be multiphasic simply by loading drug freely into the PLGA solution for burst release, or into 
PBAE microparticles for sustained release with reduced burst. This injectable scaffold provides the 
simplicity of a targeted injection with the utility of an implantable drug delivery scaffold without 
compromising desirable release kinetics. 
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Chapter 4 Hydroxyapatite-Reinforced in Situ Forming PLGA Systems for Intraosseous Injection 
4.1. Introduction 
In situ forming poly(lactic-co-glycolic acid) (PLGA) implants have been investigated 
primarily for injection into soft tissue for sustained drug delivery [195]. These systems were 
conceived due to the phase separation observed when a hydrophobic polymer dissolved in a 
water-miscible organic solvent is introduced to an aqueous environment, resulting in solidification 
of the polymer matrix [198]. By mixing drugs into the polymer phase prior to injection, a drug-
loaded, solid depot can form upon injection into the body. Such systems are available in FDA-
approved formulations, such as Atridox®, for delivery of doxycycline into gum tissue, and Atrigel®, 
which is approved for delivery of leuprolide acetate for treatment of prostate cancer. These 
systems provide prolonged drug release, with an initial burst dependent on drug and solvent 
properties and a release period dependent on drug and polymer properties [139]. As such, these 
injectable systems avoid the additional trauma that would be needed for implantation of large, 
solid dosage forms. Furthermore, PLGA is hydrolytically degradable, so there is no secondary 
surgery required to remove an implant after drug delivery is complete [218]. Because the systems 
are locally injectable and space-filling, they should theoretically be able to infiltrate and conform 
to complex geometries, such as a network of trabecular bone. 
Most research on in situ forming PLGA systems to date has focused on modifying release 
kinetics by changing solvent or polymer chemistry or concentrations [137, 200, 201]. There has 
been little focus, however, on the capability of these systems to accommodate filler particles to 
modify mechanical properties [223]. Recently, it was shown that hydroxyapatite (HA) and poly(β-
amino ester) (PBAE) additives can improve bisphosphonate and simvastatin release, respectively, 
from in situ forming PLGA systems [81]. HA has also been demonstrated to improve the 
osteoconductive and mechanical properties of pre-formed polymeric scaffolds for orthopedic 
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applications [224-226], although to date there has been no published research on the mechanical 
effects of HA additives in in situ forming PLGA scaffolds, to the authors’ knowledge. 
Many orthopedic conditions result in structurally compromised bone that would benefit 
from both pharmaceutical treatments and mechanical support. For example, avascular necrosis 
and osteoporosis reduce both bone quality and quantity, and can ultimately lead to structural 
collapse [227-229]. Trabecular bone is composed of a high-porosity, interconnected network of 
bone, and the inter-trabecular space houses marrow, adipose tissue, blood vessels, and interstitial 
fluid. This trabecular network is a potential target for intraosseous injection of an in situ forming 
system, allowing a scaffold to form a network complementary to trabecular bone.  From a 
mechanical standpoint, it is beneficial to surround weakened or necrotic bone with a structurally 
supportive material to prevent collapse, especially if that material can promote repair of the 
compromised tissue. To this end, the previously described injectable HA-PLGA-PBAE system was 
investigated for its mechanical benefits in trabecular bone. 
A necessary step in designing such a system is characterizing the mechanical effects that 
HA has on an in situ forming PLGA system. Scaffolds need to be considered both for their intrinsic 
material properties and for their ability to augment the structural properties of trabecular bone. 
Another consideration is the injectability of the system, which encompasses both force required 
to extrude the mixture as well as the potential for the injection to penetrate the trabecular bone 
network and solidify. The present studies investigated the mechanical and microarchitectural 
properties of composite HA-PLGA-PBAE injectable scaffolds, as well their space-filling and 
reinforcement effects on trabecular bone.  
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4.2. Materials and Methods 
4.2.1. Synthesis of PBAE microparticles 
 PBAE hydrogel slabs were synthesized as described previously [69, 70]. Briefly, macromer 
was created by reacting diethylene glycol diacrylate with isobutylamine at 85oC for 16 hours at a 
1.2:1 molar ratio. This macromer was then photopolymerized between two glass plates with 1% 
w/w DMPA initiator and a 1:1 weight ratio of macromer to microparticulate hydroxyapatite (MHA) 
(Sigma-Aldrich, St. Louis, MO, USA) to form a PBAE hydrogel slab. PBAE hydrogels were previously 
loaded with drug for use as delivery vehicles, but were left unloaded for these experiments. 
Microparticles were formed by grinding PBAE slabs and sieving until all collected particles were 
250 μm or less in size. 
4.2.2. NHA synthesis 
Nanoparticulate HA (NHA; nGimat, Lexington, KY, USA) was produced at nGimat LLC’s 
facility in Lexington, KY, using a solution combustion process called NanoSpray Combustion SM.  
This scalable process is capable of producing synthetic bone minerals, such as HA, tricalcium 
phosphate (TCP), and amorphous calcium phosphate (ACP), using cost-effective precursor 
materials.  To produce NHA, a calcium carboxylate precursor and an alkyl phosphate precursor of 
appropriate proportions were dissolved in an organic solvent system, the solution was converted 
to an ultrafine spray (referred to as a NanoSpray) using a device called a Nanomiser®, and the 
spray was combusted under a controlled atmosphere.  The average particle size for the NHA was 
<200 nm, as estimated by BET.  X-ray diffraction confirmed the presence of the HA phase 
(Ca5(OH)(PO4)3), and X-ray fluorescence spectroscopy showed that the Ca:P ratio was close to 5:3. 
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4.2.3. Formation of cylindrical scaffolds 
PLGA (50:50 L:G, acid terminated, inherent viscosity 0.55-0.75 dL/g ) was obtained from 
DURECT, Inc. (Birmingham, AL, USA). All experiments used a polymer solution of 30% w/w PLGA 
in NMP (Sigma-Aldrich, St. Louis, MO, USA). PBAE microparticles and MHA or NHA were mixed 
homogeneously into the polymer solution using a spatula. The scaffold mixture was loaded into a 
syringe and injected through a 16 gauge needle into a cylindrical agarose mold, where the system 
was allowed to solidify in phosphate-buffered saline (PBS). Scaffolds contained different 
concentrations of MHA or NHA, ranging from 0% to 50% w/w. All scaffolds contained 5% w/w 
PBAE microparticles to mimic prior drug release study conditions, unless otherwise indicated. PBS 
was replaced daily to prevent accumulation of NMP or low molecular weight species that were 
cleared from the scaffolds.  
4.2.4. Mechanical properties of cylindrical scaffolds 
All compression tests were performed using a Bose ELF 3300 mechanical testing 
instrument. Modulus was calculated as the slope of the initial linear region of the stress-strain 
curve (approximately the first 5-10% strain). Yield stress was determined as the stress at which 
the stress-strain curve became nonlinear. To first identify any strain rate-dependence of 
mechanical properties, scaffolds prepared with increasing MHA content were tested in 
unconstrained compression to 50% strain at displacement rates of 0.006, 0.06, and 0.6 mm/s 
(strain rates of 0.001, 0.01, and 0.01 s-1, respectively). The contribution of PBAE microparticles to 
mechanical properties was quantified by increasing PBAE content from 1% to 15% w/w in 
scaffolds prepared with 30% NHA.  
To determine the effects of NHA versus MHA on scaffold properties, a comparison of 
mechanical properties for scaffolds containing different amounts of MHA and NHA was 
performed at a displacement rate of 1 mm/min (0.0167 mm/s, or a strain rate of 0.0028 s-1) to 
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50% strain. Total HA content ranged from 0 to 50% in intervals of 10%. Scaffolds were prepared 
with either pure MHA, pure NHA, or different ratios of the two.  
4.2.5. Injectability 
To quantify injectability, scaffold mixtures containing 30% w/w NHA and 5, 10, or 15% 
w/w PBAE microparticles were loaded into a 3 mL syringe affixed with a 1.5 inch, 16 gauge needle. 
The loaded syringe was suspended by its flanges in a 15 mL centrifuge tube to collect the injected 
mixture, with the end of the tube in contact with the load cell and the plunger of the syringe in 
contact with the axial mover. The plunger was subjected to a series of sustained loads to simulate 
injection force, and the resulting displacement of the plunger was recorded. Injectability was 
quantified by plotting the time to inject 0.5 mL as a function of the injection force. Rational limits 
of 60 second injection time and 50 N injection force were set as the limits of injectability based 
on consultation with an orthopedic surgeon (T.A.M.). 
4.2.6. Microarchitecture 
Effects of HA on microarchitecture were analyzed by preparing scaffolds with increasing 
NHA and MHA content, as well as a variety of NHA/MHA mixtures totaling 30% HA, lyophilizing 
these scaffolds after they had solidified in PBS for 3 days, and then scanning them with a SCANCO 
MicroCT 40 (SCANCO Medical AG, Switzerland) at 55 kV and 145 mA and 6 μm voxel size. 
Microarchitecture was quantified by porosity and material density. Scanning electron microscopy 
(SEM) was used to visualize micro- and nanoarchitecture of scaffolds containing 30% w/w NHA. 
Samples were freeze-fractured, coated with gold-palladium alloy, and imaged with a Hitachi S-
4300 scanning electron microscope at 3 kV accelerating voltage.  
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4.2.7. Ex vivo scaffold injections 
Humeral heads were harvested from 10 week old male piglets euthanized in a separate 
study, and were kept frozen until use, without chemical fixation or removal of marrow. Using a 
16-gauge, 2.5-inch bone biopsy needle inserted through the growth plate into the proximal 
humeral epiphysis, two humeral heads each received 3 mL ex vivo injections of 30% NHA / 5% 
PBAE scaffolds. Two humeral heads were used as untreated controls. All humeral heads were 
scanned using microCT prior to injection, immersed in PBS for 5 days to allow scaffolds to fully 
solidify, and then scanned again to quantify scaffold infiltration. After 5 days in PBS, a 3 mm 
diameter cylindrical punch was used to remove tissue samples in the mediolateral direction, with 
the punch approaching through the articular cartilage and penetrating through the growth plate, 
for a total of 7 samples each for treatment and control groups. These cylindrical samples were 
trimmed to 6 mm in length, using only trabecular bone tissue between the growth plate and the 
articular cartilage. All samples were stored in PBS and tested the same day in unconstrained 
compression at a rate of 1 mm/min. 
4.3. Results 
4.3.1. Strain rate and MHA content  
 Scaffolds prepared with different MHA contents were compressed at strain rates 
spanning three orders of magnitude. At strain rates of 0.001, 0.01, and 0.1 s-1 (corresponding to 
displacement rates of 0.006, 0.06, and 0.6 mm/s), modulus increased with MHA content (Figure 
4.1A). The highest modulus increased from 64 to 82 to 96 MPa for each respective strain rate, and 
overall, moduli ranged from 9 to 96 MPa. The lowest recorded modulus for any scaffold containing 
HA was 29 MPa (10% MHA, 0.001 s-1), while scaffolds without any HA ranged from 9 to 30 MPa, 
increasing with strain rate. At 0.001 s-1, significant increases in modulus occurred between 0-10% 
(p<0.01) and 30-50% MHA (p<0.01). At 0.01 s-1, significant increases occurred between 0-20% 
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(p<0.05) and 20-50% MHA (p<0.0001). At the highest strain rate of 0.1 s-1, modulus increased 
between 0-10% (p<0.01), 10-30% (p<0.001), and 30-40% MHA (p<0.001). For equivalent scaffold 
formulations, average modulus increased with increasing strain rate in every case, and this trend 
was significant at 40% MHA between 0.01 and 0.1 s-1 (p<0.0001) and at 50% w/w MHA between 
0.001 and 0.01 s-1 (p<0.05).  
 Yield stress followed a similar trend to modulus, however the differences between 
scaffold formulations and between strain rates were less pronounced (Figure 4.1B). Yield stresses 
ranged from 1.1 to 7 MPa, and the highest yield stresses at the three strain rates of 0.001, 0.01, 
and 0.1 s-1 were 4.4, 5, and 7 MPa, respectively. Addition of 10% MHA to scaffolds led to a 
threefold increase in yield stress at a strain rate of 0.001 s-1 (from 1.1 to 3.3 MPa) and a twofold 
increase in yield stress at 0.01 s-1 (from 2 to 4.2 MPa), while 10% MHA scaffolds experienced only 
a 13% increase (from 4.5 to 5.1 MPa) at a strain rate of 0.1 s-1. At 0.001 s-1, significant increases 
in yield stress occurred between 0-10% (p<0.0001) and 40-50% MHA (p<0.01). At 0.01 s-1, yield 
stress significantly increased at 0-10% (p<0.0001) and 10-30% MHA (p<0.01). At the highest strain 
rate of 0.1 s-1, yield stress increased from 0-20% (p<0.05) and 20-50% MHA (p<0.05). Similar to 
modulus, average yield stress for equivalent scaffold formulations increased at every strain rate. 
Increasing strain rate from 0.001 to 0.01 s-1 led to an increase in yield stress for 20% (p<0.001), 
30% (p<0.01), and 40% MHA scaffolds (p<0.001). Further increasing strain rate from 0.01 to 0.1 s-
1 resulted in significantly increased yield stress for 0% (p<0.0001), 30% (p<0.01), 40% (p<0.01), 
and 50% MHA scaffolds (p<0.0001).   
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Figure 4.1. Mechanical properties of cylindrical scaffolds prepared with different MHA content 
and tested at multiple strain rates. A) Compressive modulus. B) Yield stress. Data are grouped by 
displacement rate and ordered by increasing MHA content. Shared letters denote statistical 
similarity, and columns without a single shared letter are significantly different. Data are mean ± 
standard deviation (n=3). 
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4.3.2. PBAE content 
Scaffolds prepared with 30 w/w% NHA and different PBAE microparticle contents were 
compressed at 1 mm/min (0.0028 s-1). PBAE microparticle content did not significantly affect 30% 
NHA scaffold mechanical properties for PBAE content ranging from 1 to 10 w/w %. Moduli ranging 
from 96-120 MPa (Figure 4.2A) and yield stresses from 4.3-4.9 MPa (Figure 4.2B) were recorded 
in these PBAE content ranges, with the highest modulus occurring at 10% PBAE and the highest 
yield stress occurring at 1% PBAE. Increasing PBAE content from 10 to 15% led to a significant 
decrease in modulus from 120 to 84 MPa (p<0.05). Average yield stress of 15% PBAE scaffolds was 
3.6 MPa, significantly lower than 1% PBAE scaffolds (p<0.05), which had an average yield stress of 
4.9 MPa. Samples became more viscous and difficult to inject into molds as PBAE content was 
increased. Beyond 15% PBAE, the mixture could still be injected, but the scaffold began 
precipitating before it could flow and fill the cylindrical mold, resulting in inconsistent morphology 
and unreliable mechanical properties.  
63 
 
 
Figure 4.2. Mechanical properties of 30 w/w % NHA scaffolds prepared with increasing PBAE 
microparticle content. A) Compressive modulus. B) Yield stress. Shared letters denote statistical 
similarity, and columns without a single shared letter are significantly different. Data are mean ± 
standard deviation (n=3). 
4.3.3. Ratio of MHA to NHA 
 Scaffolds prepared with different amounts of MHA and NHA were compressed at 1 
mm/min (0.0028 s-1). All scaffolds generally increased in modulus up to 30% w/w total HA content 
(Figure 4.3A). In scaffolds prepared with only MHA, a linear increase in modulus from 33 to 68 
MPa was observed from 10% through 30% MHA, although no significant difference was observed 
between groups. Modulus was significantly different between 10% and 50% MHA scaffolds 
(p<0.05). Scaffolds prepared with only NHA exhibited a large and significant increase in modulus, 
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from 53 to 141 MPa, between 20% and 30% NHA (p<0.0001). Scaffolds prepared with equal 
amounts of NHA and MHA possessed moduli similar to 30% NHA scaffolds, with 15:15, 20:20, and 
25:25 NHA:MHA scaffolds all exhibiting moduli between 128 and 151 MPa. Other scaffolds with 
similarly high moduli included mixed NHA and MHA scaffolds with total HA concentrations of 50% 
(10:40, 20:30, and 30:20 NHA:MHA). Notably, 20:10 scaffolds exhibited significantly lower 
modulus than 15:15 and 30:0 NHA:MHA scaffolds (p<0.0001). Scaffolds with 40% and 50% total 
had the highest modulus at a 1:1 NHA:MHA ratio, which decreased when the NHA:MHA ratio was 
changed in either direction.  
 Yield stress followed trends similar to modulus, however the magnitude of these 
differences was lower (Figure 4.3B). For example, out of all scaffolds prepared with 30% total HA, 
only 30:0 and 10:20 NHA:MHA samples were significantly different (p<0.01). Scaffolds made with 
40% pure MHA or 40% pure NHA had significantly lower yield stresses than scaffolds prepared 
with a mixture of NHA and MHA (p<0.01). At 50% total HA, scaffolds with 30% or higher NHA 
content possessed lower yield stresses than scaffolds composed of 25:25, 20:30, or 10:40 
NHA:MHA (p<0.01).  
65 
 
 
 
Figure 4.3. Mechanical properties of scaffolds prepared with different MHA:NHA ratios, grouped 
by increasing total HA content (w/w %) and subsequently ordered by increasing MHA content 
(w/w %). A) Compressive modulus. B) Yield stress. Shared letters denote statistical similarity, and 
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columns without a single shared letter are significantly different. Data are mean ± standard 
deviation (n=3). 
4.3.4. Injectability 
Injectable scaffold mixtures containing 5, 10, or 15 w/w% PBAE microparticle content 
were injected through a 16 gauge, 1.5 inch needle with a series of increasing injection forces. For 
each injection, the displacement of the plunger initially increased rapidly due to compression of 
the rubber plunger, the scaffold mixture, and any air bubbles, before reaching a period of linear 
displacement where flow rate was constant, followed by a relaxation period as force was removed 
(Figure 4.4A). The linear portion of the displacement curve was used to calculate displacement 
rate of the syringe plunger, and the internal diameter of the syringe barrel was used to calculate 
volumetric flow rate. The time required to inject 0.5 mL of each mixture increased with increasing 
PBAE content, and it decreased with increasing injection force (Figure 4.4B). Scaffolds were 
considered injectable if a 0.5 mL injection could be performed in 60 seconds or less, which is 
indicated by the horizontal dashed line in Figure 4B. The 5% PBAE scaffolds were injectable for 
injection forces greater than 16 N, 10% PBAE scaffolds became injectable at 40 N, and 15% PBAE 
scaffolds became injectable at 75 N. The vertical dotted line at 50 N in Figure 4B indicates the limit 
for a reasonable injection force, beyond which sustained forces may be uncomfortable or cause 
fatigue for the surgeon performing the procedure. For each scaffold composition, a logarithmic 
transformation of both injection force and injection time resulted in the best fit. 
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Figure 4.4. Injectability of 30% NHA scaffold mixtures prepared with varying PBAE microparticle 
content. A) Representative graph of collected force (green curve, left axis) and displacement (blue 
curve, right axis) data, with the highlighted linear portion of the displacement used to calculate 
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volumetric flow rate. B) Time required to inject 0.5 mL from a 16 gauge needle for various injection 
forces and PBAE microparticle contents. The dotted lines indicate reasonable limits for injection 
time for 0.5 mL (60 sec) and injection force (50 N). Data are mean ± standard deviation (n=3). 
4.3.5. Microarchitecture 
Visualizing the microarchitecture of scaffolds prepared with 30% w/w NHA and 5% w/w 
PBAE microparticles revealed two distinct levels of porosity, with NHA and PBAE particles trapped 
within the solid PLGA matrix. Macroscopic pores on the order of 100 μm in diameter were 
scattered throughout the scaffold (Figure 4.5A), and the solid PLGA matrix was primarily 
composed of a microporous, honeycomb-like structure with pore sizes on the order of 10 μm 
(Figure 4.5B). Elongated pores were observed at the scaffold surface (Figure 4.5C). HA 
nanoparticles, with spherical morphology and diameters on the order of 50 nm, were present in 
the PLGA walls of the micropores (Figure 4.5D). These particles were densely packed in 30% w/w 
NHA scaffolds.  
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Figure 4.5. SEM images of 30% w/w NHA scaffold microarchitecture, showing A) macropores on 
the order of 100 μm (white arrows), B) microporous PLGA substructure, C) elongated pores 
perpendicular to the surface (dotted arrows), and D) NHA nanoparticles embedded in the PLGA 
matrix (black arrows). 
 MicroCT analysis allowed for quantification of microarchitectural parameters such as 
porosity and material density. Porosity generally decreased with increasing total HA content, and 
this trend was most pronounced in samples prepared with only MHA, which possessed porosities 
ranging from 2.4 to 48.1%, while samples prepared with only NHA had a porosity range of 13 to 
22.5% (Figure 4.6A). MHA-only samples experienced a significant decrease in porosity from 10-
20% (p<0.001) and 30-40% (p<0.05), and NHA-only samples had a significant decrease in porosity 
from 10-30% (p<0.05). Samples with 30% total HA prepared with different mixtures of MHA and 
NHA did not exhibit significantly different porosity from each other. At equivalent weight 
percentages, samples prepared with pure NHA had significantly lower porosity than those 
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prepared with MHA at 10% (p<0.0001), 20% (p<0.001), and 30% (p<0.05), while porosity between 
the two groups was not different at 40% and 50% w/w.  
 Material density increased with total HA content, and scaffolds prepared with NHA 
experienced a larger increase in density at each 10% increment of HA content (Figure 4.6B). MHA 
scaffolds exhibited significantly higher density than NHA scaffolds at 10% (p<0.0001) and 20% 
(p<0.01), but due to the smaller rate of increase, they exhibited lower density than NHA scaffolds 
at 30%, 40%, and 50% w/w (p<0.0001). The 30% HA scaffolds prepared with a mixture of NHA and 
MHA had lower density at 10:20 NHA:MHA formulations than scaffolds prepared with 15:15 and 
20:10 NHA:MHA (p<0.0001).  
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Figure 4.6. MicroCT analysis of scaffolds prepared with varying NHA and MHA content, showing 
A) porosity and B) material density of cylindrical samples. Data are grouped by total HA content, 
and ordered by increasing NHA content. Shared letters denote statistical similarity, and columns 
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without a single shared letter are significantly different. Data are mean ±- standard deviation 
(n=3). 
4.3.6. Ex vivo scaffold injections 
During the injection of scaffolds into the humeral heads, fluid was observed leaking out 
of bone near the growth plate, indicating that the scaffold was displacing marrow and filling the 
intertrabecular space. After the 3 mL injection into two humeral heads, there was an average 
reduction in free volume of 2.8 mL, corresponding to a 58% filling of the intertrabecular volume 
(data not shown). A comparison of cutplanes from a 3D reconstruction of the humeral heads 
showed scaffold material distributed throughout the bone volume, with small (sub-millimeter) 
regions of that were unfilled (Figure 4.7A). During removal of the cylindrical cores from injected 
bones, it was observed that scaffold material was constrained by the articular cartilage and 
growth plate (Figure 4.7B). Cylindrical samples of injected bone possessed a mean compressive 
modulus of 180 MPa, compared to 81 MPa for controls (p<0.001) (Figure 4.7C). Yield stress was 
also significantly higher for injected bone, with a yield stress of 5.9 MPa for injected samples 
compared to 3.5 MPa for controls (p<0.01) (Figure 4.7D).  
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Figure 4.7. Microstructural and mechanical properties of trabecular bone samples from porcine 
humeral heads with or without injection of 30% NHA / 5% PBAE scaffolds. A) MicroCT cutplane of 
humeral head prior to injection (left) and post-injection (right). B) Cylindrical bone sample 
containing solidified scaffold. C) Compressive modulus. D) Yield stress. Data are mean ±- standard 
deviation (n=7). *Significantly different from Control (p<0.001). **Significantly different from 
Control (p<0.01). Scale bar is 5 mm. 
4.4. Discussion 
4.4.1. Mechanical properties 
 The general effects of HA additives on in situ forming PLGA scaffolds were consistent with 
existing research on preformed, implantable scaffolds [224, 230-232], with HA additives providing 
mechanical reinforcement, as evidenced by both compressive modulus and yield stress. As HA 
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content was increased beyond a certain point (generally around 30% w/w, depending on the 
specific MHA and NHA content), mechanical properties either plateaued, in the case of MHA, or 
decreased, in the case of NHA. This effect can be attributed to the total surface area of HA relative 
to the volume of PLGA, which results in maximal scaffold mechanical properties when sufficient 
PLGA is present to bind HA together tightly without excess HA or PLGA. SEM images of the 30% 
NHA scaffolds showed dense packing of NHA nanoparticles embedded in the PLGA phase, which 
may explain why further increasing NHA content was not beneficial since particles were already 
in close proximity at this loading. MHA scaffolds were mechanically inferior to NHA at equivalent 
concentrations, likely due to the lower surface area to volume ratio of MHA, which allowed fewer 
PLGA:HA and HA:HA interfaces to form, and thus led to a more loosely packed HA microstructure. 
Additionally, there may exist a critical threshold for particle size, below which significant 
mechanical benefits occur in a composite [233]. Scaffolds with a higher NHA and MHA packing 
capacity could potentially be created by increasing PLGA concentration in the PLGA/NMP solution 
[232], however, this would also increase the viscosity of the injectable mixture [234]. 
 Interestingly, scaffolds prepared with equal amounts of NHA and MHA tended to possess 
comparable mechanical properties to scaffolds prepared with pure NHA or pure MHA. This 
similarity may be due to the tight packing of NHA in the spaces between MHA particles, resulting 
in scaffolds that are effectively identical to tightly packed NHA when compressed. Ultimately, the 
similarity between pure NHA and equally mixed NHA/MHA scaffolds is probably the result of two 
factors: 1) HA should be present at sufficient concentrations so that load is primarily being 
transmitted between tightly packed HA particles, and 2) enough PLGA should be present so that 
it can bind all the HA particles together. For a system intended for intraosseous injection, 
however, 30% NHA provides the highest mechanical properties at the lowest total HA 
concentration, and was therefore the most appealing formulation in terms of injectability.  
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 Native trabecular bone in human femoral heads has a wide range of mechanical 
properties, with compressive moduli ranging from 100-600 MPa and yield strength ranging from 
1-9 MPa [227, 235]. For conditions that may be candidates for an injectable, intraosseous 
treatment, these values may be reduced by 24% (yield stress) and 20% (modulus) in osteoporotic 
patients [227], or 50% (yield stress) and 72% (modulus) in osteonecrosis patients [235].  Scaffolds 
with material properties similar to trabecular bone can aid load-bearing while the drug delivery 
component of the scaffold exerts its effect [236]. The average modulus of scaffolds prepared with 
30% NHA was 141 MPa, and the average yield stress was 6.2 MPa, which are both within the range 
of trabecular bone. Although in situ forming PLGA systems have not been extensively investigated 
for their mechanical properties, the strength of these scaffolds is 10-fold higher than a similar 
system containing 33% α-tricalcium phosphate and PLGA of a lower molecular weight [223]. 
Furthermore, the yield stress was on the higher end of healthy trabecular bone, so even if 
scaffolds are slightly less stiff than the native bone tissue, they can withstand similar stresses to 
healthy bone before beginning to collapse. It is important to consider these scaffolds as a means 
for temporary augmentation that can acutely preserve bone while treatment occurs, not as a 
replacement for healthy bone tissue. For this purpose, the material properties of the 30% NHA 
system are sufficient.  
4.4.2. Injectability 
Injectability is a unique concern for in situ forming scaffolds, because both HA and PBAE 
particle additives increase viscosity. Becaue prior injectable PLGA systems were not intended for 
mechanical support, and drug is usually mixed freely into the polymer solution, viscosity has not 
been a limiting factor when designing these systems. However, injectable bone cements and 
fillers have encountered issues with injectability because they are composed of a liquid phase 
containing high concentrations of suspended particles [237, 238]. For example, decreasing the 
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liquid to powder ratio increases the required injection force and decreases the extruded fraction 
[237, 239], which is roughly analogous to increasing HA content in an injectable PLGA system. 
Various additives have been investigated to decrease the required injection force [240]. 
Injectability will likely be a persistent, nontrivial issue for in situ forming PLGA systems containing 
mechanical filler. Setting NHA content to a constant 30% and varying PBAE microparticle content 
revealed that there is a clear limit on PBAE microparticle content (and, therefore, drug loading) 
beyond which the system cannot be injected without exceeding limits of injection force or 
injection time. Longer-duration injections may be complicated by the precipitation of PLGA into a 
solid [241], leading to increased backpressure and a loss of injectability, while injections requiring 
large sustained force may be uncomfortable for the surgeon performing the procedure. The 
injection force limit may be circumvented by the use of an injection gun, which would improve 
injection time and greatly increase the injection force limit. 
4.4.3. Ex vivo injections 
 The space-filling and mechanical reinforcement potential of an injectable system is likely 
to differ in situ from simulated tests, due to the presence of a constrained geometry filled with 
marrow and bordered by anatomical features such as articular cartilage, cortical bone, and the 
growth plate. The incomplete filling of free volume by the scaffold suggests that the material 
establishes flow channels of low resistance, resulting in small pockets of unfilled bone. MicroCT 
images and cylindrical tissue samples, however, show that these unfilled regions are distributed 
throughout the bony network, and the scaffold was capable of filling the bone tissue in all 
directions. Furthermore, injected bone tissue was significantly stronger and stiffer than native 
tissue, suggesting that the 58% filling that was achieved is sufficient to greatly improve mechanical 
properties of trabecular bone.  
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4.4.4. Advantages of the system 
An in situ forming HA-PLGA-PBAE implant offers several advantages over traditional 
orthopedic injectables, such as poly(methyl methacrylate) (PMMA) bone cement. The heat of free 
radical polymerization of PMMA in situ can lead to protein denaturation and tissue necrosis [242], 
whereas in situ forming PLGA scaffolds are formed via solvent exchange at ambient temperature. 
PMMA is not biodegradable, while PLGA degrades hydrolytically over a time period dependent on 
its chemical properties [218]. Biodegradation is important for a drug delivery scaffold embedded 
in a trabecular network, where removal surgery is impossible and a permanent implant is not 
ideal. Finally, the mechanical properties of PMMA are a better match for cortical bone than a 
trabecular bone network, while PLGA is a less stiff material that may be appropriately augmented 
to match trabecular bone via addition of HA filler [236, 243]. An implant that acutely reinforces 
compromised bone, controls drug release, and gradually degrades to allow regeneration of native 
tissue can provide a comprehensive treatment in a single injection.  
4.5. Conclusions 
 The present study demonstrated the feasibility of an injectable PLGA scaffold containing 
PBAE and HA particles as a mechanically supportive, in situ forming scaffold. Injectable scaffold 
mixtures are capable of being injected through a standard bone biopsy needle, infiltrating 
trabecular bone, then solidifying to produce scaffolds with mechanical properties comparable to 
those of trabecular bone. This injectable scaffold offers a promising treatment platform for 
ailments requiring both drug delivery and mechanical reinforcement of trabecular bone, and it 
has the advantage of being easily injectable and fully resorbable. This particular system was 
optimized to accommodate NHA mechanical filler and PBAE microparticles for drug delivery, with 
the goal of an intraosseous injection into the femoral head. In situ forming PLGA systems have 
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traditionally been viewed purely as drug delivery devices, but this study clearly demonstrates the 
potential for a mechanical component to these systems as well.  
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Chapter 5 Poly(β-amino ester) hydrogel microparticles to improve in situ forming delivery 
systems for periodontitis 
5.1. Introduction 
Periodontitis is a complex oral infection, in which bacteria colonize below the gum line, 
leading to the destruction of multiple tissues, including the gingiva, alveolar bone, and 
periodontal ligament [151]. Beyond the progressive deterioration of oral health leading to tooth 
loss, periodontitis has also been implicated in systemic conditions such as cardiovascular and 
cerebrovascular disease, and diabetes [153, 154]. Traditionally, periodontitis is treated with 
mechanical removal of bacteria from tissue surfaces in a process called scaling, followed by 
smoothing of the tooth surface, called root planing [157]. In many cases, scaling and root 
planing are accompanied by local or systemic delivery of antibiotics to treat difficult infections 
and to prevent recurrence [158]. However, systemic antibiotics can lead to adverse side effects 
due to the relatively high dosage required to provide sufficient concentration in oral tissues, and 
simple local delivery, such as rinses, needs to be repeated frequently to maintain appropriate 
antibiotic concentrations. Therefore, local delivery systems have been developed to maintain 
antibiotic dosages within the periodontal pocket [244-246]. In advanced cases of periodontitis, 
significant alveolar bone loss occurs, and augmentation procedures involving implanted grafts or 
scaffolds may be used to promote bone regrowth after the infection has been cleared [151, 
247].  
A single, injectable therapy, containing both antibiotic and osteogenic components in a 
biodegradable scaffold, can potentially provide an all-encompassing, minimally invasive 
treatment for this condition. The commercially available Atridox® system is an injectable 
formulation of poly(lactic-co-glycolic acid) (PLGA) containing doxycycline, an antibiotic, and has 
been shown to maintain local doxycycline concentrations above the minimum inhibitory 
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concentration for over 1 week. Recently, a similar system containing particulate additives for 
orthopedic applications was investigated for delivery of simvastatin, which has osteogenic and 
anti-inflammatory properties [81].  
Historically, little focus has been placed on these in situ forming implants (ISIs) for their 
potential as scaffolds for new tissue growth. This is due to the dense, solid microstructure, 
which is not conducive to cellular infiltration [248], as well as the tendency of these implants to 
loosen within the periodontal pocket, which can also lead to fragments of polymer breaking off 
and dislodging.[246]  Incorporation of degradable or soluble porogen particles into delivery 
systems improves the microstructure of these scaffolds [248], and incorporation of bioadhesive 
polymers and plasticizers was shown to improve adhesive properties [249]. The mechanical 
properties of ISIs, as well as the physical changes (i.e., swelling and microarchitectural changes), 
are important for periodontal applications, because the periodontal pocket presents a 
constrained geometry that is subject to cyclical stresses from chewing, and compared to the 
gingiva, PLGA is a stiff material prone to plastic deformation. Conceivably, a highly porous 
material that swells to fill the pocket and releases both antibiotic and osteogenic stimuli may be 
beneficial for future consideration as a scaffold for tissue regeneration. Biodegradable poly(β-
amino ester) (PBAE) hydrogel microparticles have been used previously to modulate both drug 
release and microarchitecture of PLGA ISIs designed for orthopedic applications [81]. A first step 
towards testing adapting PBAE-loaded PLGA ISIs for periodontitis is to quantify the drug release 
and material changes due to these additives. Therefore, the aim of this study was to 
demonstrate acute antibiotic delivery accompanied by co-delivery of an antibiotic and an 
osteogenic agent from PBAE-containing PLGA ISIs, and to quantify the effects of these PBAE 
additives on swelling, degradation, microarchitecture, and mechanical properties. 
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5.2. Materials and Methods 
5.2.1. Materials 
Diethylene glycol diacrylate and poly(ethylene glycol) 400 diacrylate (PEG400DA) were  
bought from Polysciences, Inc. (Warrington, PA). 2,2-Dimethoxy-2-phenylacetophenone 
(DMPA), high molecular weight PLGA (HMW PLGA; 50:50 lactide:glycolide, 0.55-0.75 dL/g in 
hexafluoroisopropanol, carboxylate-terminated), low molecular weight PLGA (LMW PLGA; 50:50 
lactide:glycolide, 0.15-0.25 dL/g in hexafluoroisopropanol, carboxylate terminated) were 
purchased from DURECT (Birmingham, AL). N-methyl-2-pyrrolidone (NMP), gelatin (from porcine 
skin, type A), glutaraldehyde (25%, grade I), agarose, trifluoroacetic acid (TFA), doxycycline 
hyclate, and glycine were obtained from Sigma Aldrich (St. Louis, MO). Simvastatin was from 
Haorui Pharma-Chem (Edison, NJ).  
5.2.2. PBAE hydrogel preparation 
 PBAE macromer was created by reacting a diacrylate with isobutylamine at 85°C for 48 
hours. Macromers were named according to the classification system from Anderson et al., in 
which the letter corresponds to a specific diacrylate and the number corresponds to a specific 
amine [69]. Thus, macromer made by reacting PEG400DA with isobutylamine for 48 hours was 
termed H6. A macromer containing a 2:1 molar ratio of diethylene glycol diacrylate:PEG400DA 
was also created, and will subsequently be referred to as AH6. 
PBAE hydrogels were formed by adding 0.1% w/w DMPA, dissolved in ethanol, to the 
macromer, pipetting this mixture between two parallel glass plates, and exposing the mixture to 
a 365 nm UV flood source for 5 minutes to crosslink the macromer. The resulting hydrogels were 
washed overnight in ethanol to remove residual DMPA and unreacted monomers, and were 
stored in a desiccator until use. 
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 PBAE microparticles were made by swelling PBAE hydrogels in ethanol for 1 hour and 
then grinding them with a mortar and pestle. The slurry was passed through a 250 μm sieve 
using an ethanol wash, and any larger particles were re-ground until 100% of the hydrogel was 
sieved. The microparticle slurry was lyophilized, and the resulting microparticles were stored in 
a desiccator.  
5.2.3. Injectable mixture formulations 
 A PLGA solution was formed by dissolving 30% or 40% w/w of either HMW or LMW 
PLGA in NMP overnight. PBAE microparticles (H6, AH6, or a mixture of the two) were added to 
the PLGA solution at 10% w/w and stirred until the mixture was homogeneous. 2% w/w 
simvastatin or doxycycline (or 2% w/w each for co-delivery) were added to the PLGA-PBAE-NMP 
suspension and mixed thoroughly. Alternatively, doxycycline was pre-loaded into AH6 
microparticles by swelling the microparticles with a 3 mg/mL doxycycline solution in acetone at 
a ratio of 100 mg AH6 to 500 µL of solution. These swollen particles were lyophilized for 24 
hours, resulting in doxycycline pre-loaded into AH6 microparticles. Pre-loaded AH6 
microparticles at 10% w/w in PLGA solutions were then used in drug release studies. HMW 
formulations containing simvastatin were tested first, and the most promising mixtures were 
used in subsequent tests with doxycycline and/or LMW PLGA. Table 5.1 contains a list of all 
scaffold formulations that were examined for these drug release studies.  
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Table 5.1. Scaffold formulations investigated for drug release. S = simvastatin. D = doxycycline. 
HMW = high molecular weight PLGA. LMW = low molecular weight PLGA. (Pre) indicates drug 
was pre-loaded into PBAE microparticles. “+” indicates co-delivery from the same scaffold. 
Scaffold Name PLGA PLGA % PBAE Drugs 
HMW-AH HMW 30 AH6 S / D / S+D / D(Pre)  
HMW-H HMW 30 H6 S  
HMW-H/AH HMW 30 AH6+H6 S 
HMW-Control HMW 30 None S / D  
LMW-AH LMW 30 AH6 S / D / S+D 
LMW-Control LMW 30 None S / D / S+D  
40LMW-AH LMW 40 AH6 S / D / S+D / D(Pre) 
40LMW-Control LMW 40 None S / D / S+D / D(Pre) 
 
5.2.4. Microstructure and mass change 
 To observe changes in ISI mass and microstructure, the following drug-free formulations 
were prepared: HMW-AH, HMW-H, HMW-H/AH, HMW-Control, LMW-AH, and LMW-Control 
(Table 5.1). In a 96-well plate, approximately 10 mg of injectable scaffold mixture was injected 
dropwise from an 18-gauge needle into 300 µL PBS. The syringe was weighed after each 
injection to calculate the mass of each scaffold. PBS was replaced daily to prevent buildup of 
degradation byproducts. At each time point, 3 scaffolds from each group were removed, dabbed 
dry, and weighed to measure the wet mass. For HMW scaffolds, scaffolds were collected at 1 
day and 5 days following the injection, and for every 5 days thereafter. For LMW scaffolds, 
scaffolds were collected at 1 day, 2 days, and every other day thereafter. All collected ISIs were 
lyophilized for 24 hours and weighed again to determine dry mass. HMW scaffolds were then 
scanned using a SCANCO MicroCT 40 (SCANCO Medical AG, Switzerland) with X-ray parameters 
of 55 kV and 145 mA, and a 6 μm voxel size. A built-in bone trabecular morphometry analysis 
tool was used to create 3-D reconstructions, and measurements of porosity, mean pore size, 
and material density were conducted. To quantify accessible volume and surface area, 
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simulated mercury intrusion porosimetry was run on the 3-D reconstructions using an included 
script. At select time points, samples were freeze-fractured, and a Hitachi S-4300 scanning 
electron microscope (SEM) at 4 kV accelerating voltage was used to visualize the 
microarchitecture of scaffolds.  
5.2.5. Mechanical tests 
All mechanical tests were performed with a Bose ELF 3300 system. Gelatin slabs (20%) 
measuring 8 mm thick was prepared, and were crosslinked by immersing overnight in 5 mM 
glutaraldehyde. The aldehyde groups were quenched by immersing crosslinked gelatin slabs in a 
50 mM glycine solution for 2 hours and washing serially in deionized water. Cylindrical samples 
(4 mm in diameter) were punched out of the slabs, and their mechanical properties were 
characterized by compressing these cylindrical samples to 10% strain at a frequency of 1 Hz for 
30 seconds to mimic chewing conditions [250]. The slabs containing cylindrical holes were used 
as molds to inject HMW-Control and HMW-AH scaffolds measuring 8 mm length by 4 mm 
diameter. After injection, the molds were capped with 2% agarose slabs, clamped shut lightly to 
prevent extrusion of material due to swelling, and immersed in PBS. After 3, 6, 9, 12, or 15 days, 
the solidified samples within the molds were subjected to a displacement rate of 0.5 mm/sec. 
The interfacial shear strength required for push-out was calculated by dividing the maximum 
push-out force by the scaffold surface area in contact with the mold. Cylindrical scaffolds that 
had been pushed out of their molds were tested for their compressive properties under 1% 
strain triangular waves applied at a frequency of 1 Hz for 60 seconds. The initial modulus was 
determined from the first compression cycle, and the equilibrium modulus was measured during 
the final cycle. Resilience was calculated by integrating the linear region of the stress-strain 
curve. 
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5.2.6. Drug release 
 Approximately 100 mg of each mixture (Table 5.1) was injected dropwise into 1 mL PBS 
(n=3), where the PLGA rapidly solidified into droplet-shaped scaffolds. At each time point, 
supernatant was entirely removed, stored in a refrigerator, and replaced with fresh PBS. A 
Hitachi Primaide HPLC system with a C18 column was run isocractically at 1 mL/min with a 
mobile phase composed of 70% acetonitrile / 30% water + 0.1% TFA  to detect simvastatin at 
240 nm. Collected supernatant was mixed with ethanol at a 2:1 supernatant:ethanol ratio to 
dissolve any precipitated simvastatin prior to HPLC analysis. Doxycycline was assayed using a 
mobile phase composed of 30% acetonitrile / 70% water + 0.1% TFA running at 1 mL/min and 
with detection at 350 nm.  
5.3. Results 
5.3.1. Mass change 
HMW-Controls exhibited little dry mass change through the first 15 days of degradation, 
after which a linear decrease in mass of 4.8%/day occurred through day 30 (Figure 1A). A 
significant (p<0.05) decrease in mass was observed at each time point from day 20 and onward. 
Over the first 5 days, the wet mass of these scaffolds decreased significantly (p<0.05) at a rate of 
9.4%/day, then increased slightly between days 10 and 20, before gradually declining through 
day 35, although none of these later changes was significant (Figure 1B). Both HMW-AH and 
HMW-H/AH scaffolds exhibited a small wet mass loss in the first day, followed by a relatively 
linear 6.5%/day wet mass increase through day 30 to a maximum of 273% of original mass.  At 
day 35, scaffolds fell apart upon handling and measurable mass decreased to 93% of the initial. 
HMW-H scaffolds had a larger wet mass loss of 37% (p<0.05) after 1 day, and between days 5 
and 25, an 8.6%/day mass increase occurred. A plateau was reached between days 25 and 30 
prior to a large decrease in mass at day 35. After a 1-day dry mass loss of 12%, HMW-AH 
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scaffolds lost mass at a rate of 1.7%/day until day 10. Mass loss resumed at day 15 and 
continued at a rate of 0.87%/day until day 30. HMW-H/AH scaffolds had a dry mass loss of 26% 
after day 1, and no significant mass change followed through day 30. Similarly, HMW-H scaffolds 
exhibited a large initial dry mass loss of 38% after 1 day, and no significant subsequent mass loss 
occurred until day 30 (p<0.05). 
LMW-Controls exhibited a gradual dry mass decrease to 89% after 8 days, after which 
the mass decreased linearly at a rate of 3%/day through day 30 (Figure 5.1C). LMW-Control wet 
mass rapidly increased to 193% through the first 5 days, then sharply declined and fluctuated 
around 150% through day 16 (Figure 5.1D). Beyond day 16, a linear mass loss of 7%/day 
occurred through day 30. LMW-AH scaffolds decreased steadily in dry mass at a rate of 5%/day 
for the first 8 days, followed by a brief plateau through 12 days, and terminating with a linear 
mass loss of 2%/day through day 30. LMW-AH wet mass increased for the first 5 days and 
plateaued, fluctuating around 150% through day 16. After day 16, a mass loss of 7%/day 
occurred through day 30.  
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Figure 5.1. Mass loss of ISIs. Remaining dry mass of A) HMW scaffolds and C) LMW scaffolds. 
Remaining wet mass of B) HMW scaffolds and D) LMW scaffolds. Data are mean +/- standard 
deviation (n=3). 
5.3.2. Microarchitecture 
 The microarchitecture of HMW-Controls changed dramatically throughout the first 15 
days of degradation, leading to collapse, while HMW ISIs containing PBAE additives possessed a 
more uniform pore structure and swelled visibly throughout the 15 day period (Figure 5.2). After 
1 day, HMW-Controls were composed of a dense solid phase with large, homogeneously 
distributed spherical pores. By day 5, some large pores remained in the core of the scaffold, 
while most were present near the edges and were oriented radially. By day 10, the radial pores 
were more numerous, surrounding the dense core, and by day 15, the scaffolds had collapsed. 
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HMW-H scaffolds possessed a uniformly porous microstructure by day 1, and there were little 
microstructural changes until day 15, when noticeable swelling had occurred. HMW-AH and 
HMW-H/AH scaffolds both initially possessed porous networks with radiopaque regions inside 
these pores, which is indicative of non-degraded PBAE material (Figure 2, arrows). By day 5, 
scaffolds were noticeably swollen, and there was little evidence of non-degraded PBAE material, 
resulting in a uniformly porous microstructure; the swelling increased progressively through day 
15. None of the scaffolds containing PBAE additives collapsed within the 15-day period. 
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Figure 5.2. 3-D micro CT reconstructions, bisected, of HMW ISIs containing no additives (Control) 
or 10% PBAE particles (H, AH, or H/AH). White indicates material present in the cut plane. Arrows 
indicate solid material within pores 
HMW ISIs generally increased in both porosity (Figure 5.3A) and volume (Figure 5.3B) as 
they degraded. Specifically, HMW-Controls initially possessed 24% porosity, which increased to 
a maximum of 54% at day 10, and then declined slightly to 46% by day 15. All PBAE-containing 
scaffolds steadily increased throughout the 15-day period, with initial porosities ranging from 
42% (HMW-AH) to 55% (HMW-H). All PBAE-containing ISIs possessed significantly higher 
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porosities than HMW-Controls at all time points (p<0.001). Among PBAE-containing ISIs, only 
HMW-AH at day 1 differed significantly in porosity from others. Scaffold volume, normalized to 
initial mass, showed that HMW-Controls increased slightly in volume by day 5 before gradually 
declining (Figure 3B), and had significantly lower volume than all PBAE groups throughout 
degradation (p<0.01). HMW-H exhibited an initial decrease in scaffold volume between days 1 
and 5, followed by a linear increase beyond the initial volume by day 15. Both HMW-AH and 
HMW-H/AH generally increased in volume throughout the 15 day period.  
Accessible volume was measured for various simulated penetrating sphere diameters 
ranging from 12 µm to 120 µm, and the volume accessible by a 24 µm sphere was compared 
between groups over 15 days (Figure 5.3C). This diameter approximates the size of the 
progenitor cells that may migrate into these pores [251, 252]. At day 1, HMW-Control and 
HMW-AH possessed significantly lower accessible volume than HMW-H and HMW-AH samples 
(p<0.01). At day 5 and beyond, all PBAE-containing ISIs possessed similar accessible volumes, 
which increased from 34-38% at day 5 to 65-78% by day 15. From days 5 through 15, controls 
had significantly lower accessible volume (p<0.001). Accessible surface area was normalized to 
initial scaffold mass, and measured using the same 24 µm penetrating sphere size (Figure 5.3D). 
The trends for accessible surface area were similar to accessible volume, with HMW-Control and 
HMW-AH initially possessing significantly lower values than HMW-H and HMW-AH (p<0.01).  
Controls remained significantly lower than all other groups for each subsequent time point 
(p<0.001). HMW-AH increased linearly in accessible surface area through day 15 before 
plateauing, while both HMW-H/AH steadily increased in accessible surface area throughout 
degradation. HMW-H remained relatively unchanged between days 1-5 before increasing 
linearly through day 15.   
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Figure 5.3. Microarchitecture of HMW scaffolds throughout degradation. A) Porosity and B) 
mass-normalized volume of scaffolds, evaluated using micro CT. Accessibility of C) scaffold 
volume and D) mass-normalized surface area to a simulated 24 µm sphere. Data are mean ± 
standard deviation (n=3). 
5.3.3. Interfacial strength and mechanical properties 
 The interfacial strength in cylindrical gelatin molds, as measured by maximum push-out 
force, decreased over 15 days for HMW-Controls and increased over the same period for HMW-
AH (Figure 5.4). For HMW-Controls, at 3 days, the interfacial strength was 1.2 kPa, and 
decreased relatively linearly until it was significantly reduced to 0.5 kPa by day 12 (p<0.05). The 
interfacial strength of HMW-AH samples increased significantly from 4.7 kPa at day 3 to 8.8 at 
day 6 (p<0.01), and the interfacial strength continued to increase, although not significantly, to 
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11 kPa by day 15. At every time point, the interfacial strength of HMW-AH significantly exceeded 
that of HMW-Controls (p<0.001).  
 LMW samples exhibited a less dramatic difference between AH and Control groups 
(Figure 5.4).  LMW-Controls remained significantly higher than HMW-Controls and lower than 
HMW-AH at all time points (p<0.01), with interfacial strengths ranging from 2.7 to 5 kPa. LMW-
AH interfacial strength increased from 5.2 at day 3 to 8.7 by day 9, then decreased down to 5.3 
by day 15.  LMW-AH samples possessed significantly higher interfacial strength than LMW-
Controls for the first 12 days tested (p<0.005), and the interface remained similar to HMW-AH 
samples until days 12 and 14, which were both significantly lower than corresponding HMW-AH 
interfacial strengths (p<0.01).  
 
Figure 5.4. Interfacial strength measured from push-out tests on cylindrical samples within 
gelatin molds. Data are mean ± standard deviation (n=3). 
 Both HMW-Control and HMW-AH cylindrical samples exhibited initial and 30-cycle 
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through day 15 (Figure 5.5A). For HMW-Controls, initial modulus ranged between 48 and 61 
MPa through the first 12 days, and then a significant decrease to 25 MPa occurred (p<0.01). 
Significant changes in HMW-AH samples were detected only between day 15 and days 6 or 9 
(p<0.05), and over the 15-day period, these moduli ranged from a minimum of 14 MPa at day 15 
to 29 MPa at day 9. The 30-cycle modulus did not change in HMW-Controls for the first 9 days, 
with moduli ranging from 94 to 102 MPa. Significant decreases occurred at day 12, to 58 MPa, 
and at day 15, to 17 MPa (p<0.0001). Modulus ranged from 24 MPa at day 3 to 34 MPa by day 9, 
and then decreased significantly to 14 MPa by day 15 (p<0.001). The ratio of the initial to the 30-
cycle modulus did not change significantly throughout the 15 day period in HMW-AH samples, 
and it ranged from 0.95 at day 15 to 1.16 at day 9 (Figure 5.5B). In HMW-Controls, the modulus 
ratio ranged from 1.67 to 1.88 over the first 9 days, and then decreased significantly to 1.2 by 
day 12 and 0.7 by day 15 (p<0.01).  
 HMW-Controls and HMW-AH samples increased in resilience between days 3 and 6 
before declining through day 15, and HMW-Controls exhibited the highest initial resilience and 
the lowest 30-cycle resilience (Figure 5.5C). Resilience from the initial compression cycle of 
HMW-Controls increased significantly from 1 J/m3 at day 3 to 3.1 J/m3 at day 6 (p<0.0001), and 
then decreased significantly at day 12 to 0.97 J/m3 (p<0.0001). The 30-cycle resilience followed 
the same trend, with 0.35 J/m3 at day 3, which increased significantly to 0.9 J/m3 by day 6, then 
dropped significantly to 0.25 J/m3 by day 12 (p<0.001). The ratio of the initial to the 30-cycle 
resilience through the first 12 days ranged from 0.26 to 0.33, and a significant decrease occurred 
between days 9 and 15, down to 0.15 (p<0.05) (Figure 5.5D). HMW-AH initial resilience 
increased significantly between days 3 and 6, from 0.73 to 1.7 J/m3 (p<0.001). The resilience did 
not change until day 15, when a significant decrease occurred from 1.53 J/m3 at day 9 to 0.79 
J/m3 at day 15 (p<0.01). The 30-cycle modulus of HMW-AH samples increased significantly from 
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0.46 J/m3 at day 3 to 1.28 J/m3 at day 6 (p<0.0001), with subsequent significant decreases at day 
12, to 0.83 J/m3 (p<0.01), and at day 15, to 0.52 J/m33 (p<0.05). The ratio of these two resilience 
values for HMW-AH samples did not change significantly throughout the 15 day period.  
 LMW-Controls possessed uniformly higher ratios of initial to 30-cycle modulus at each 
time point compared to LMW-AH, though this difference was only significant at days 3 and 12 
(p<0.05) (Figure 5.5F). Similar to HMW samples, LMW-AH samples exhibited an initial to 30-
cycle modulus ratio ranging from 0.94 to 1.13. While LMW-Control initial modulus increased 
steadily from 3.2 to 8.6 MPa between days 3 and 12, LMW-AH initial modulus fluctuated from 
3.7 to 12 MPa, with a maximum at 9 days and a minimum at 12 days, resulting in no clear trend 
(Figure 5.5E). The initial resilience of both LMW-AH and LMW-Control was highest at day 12, and 
in all cases, the 30-cycle resilience was lower than the initial value for both LMW-AH and LMW-
Control (Figure 5.5G). However, the ratio of initial to 30-cycle resilience of LMW-AH, ranging 
from 0.46 to 0.56, was significantly higher at every time point than the same ratio for LMW-
Control (p<0.05), which ranged from 0.15 to 0.33 (Figure 5.5H).  
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Figure 5.5. Mechanical properties of HMW (A-D) and LMW (E-H) cylindrical implants subjected 
to 30 cycles of 1% compressive strain at 1 Hz. A,E) Initial and 30-cycle modulus. B,F) Ratio of 
initial to 30-cycle modulus. C,G) Initial and 30-cycle resilience. D,H) Ratio of initial to 30-cycle 
resilience. Data are mean ± standard deviation (n=3). 
5.3.4. Drug Release 
 HMW scaffolds loaded with simvastatin released simvastatin over 90 days, and scaffolds 
containing PBAE microparticles produced release profiles with distinct regions of different 
release rates (Figure 5.6A). HMW-Controls exhibited a significantly higher 1-day burst of 36% 
(p<0.001), compared to all PBAE-containing groups, which all had a burst of 6% or less. HMW-
Controls exhibited a declining daily release rate over the course of 40 days, with residual 
simvastatin released over the last 40 days as scaffolds completely degraded. HMW-H exhibited a 
relatively linear release rate of 1%/day through day 30, followed by a period of minimal release 
through day 60. HMW-AH had a release rate of 2.8%/day for the first 13 days, followed by a 
period of 1%/day through day 30 and then 0.25%/day through day 50. HMW-H/AH had release 
rates of 2.1%/day through day 13, 1%/day through day 30, and then 0.2%/day through day 50. 
Beyond day 60, the remaining drug was released through day 90 as scaffolds completely 
degraded. 
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 LMW scaffolds released simvastatin through 30 days, and AH6 microparticle additives 
reduced burst for each formulation (Figure 5.6B). LMW-Controls had 47% burst followed by a 
roughly linear release rate of 2.1%/day through day 30. The burst was reduced to 21% for 
40LMW-Controls, after which the release rate steadily declined through day 30. There was no 
difference in simvastatin release kinetics between LMW-AH scaffolds containing simvastatin 
alone or doxycycline and simvastatin together. Both LMW-AH and 40LMW-AH scaffolds had no 
appreciable burst, and linear release rates ranged from 2.3 to 2.5%/day through days 24 and 26, 
respectively. At day 24 or 26, the release rate increased to 10%/day until all drug was released.  
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Figure 5.6. Simvastatin release from A) HMW and B) LMW scaffolds. D+S indicates that scaffolds 
were co-loaded with simvastatin and doxycycline. Data are mean ± standard deviation (n=3). 
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 Doxycycline exhibited similar release patterns from both HMW (Figure 5.7A) and LMW 
ISIs (Figure 5.7B), with no difference observed between PBAE-containing scaffolds and controls. 
Pre-loading doxycycline into PBAE microparticles resulted in a 1-day burst similar to controls, 
but with significantly more drug released over the remainder of the week. In all cases where the 
antibiotic was not pre-loaded into AH6 microparticles, the release plateaued within one or two 
days, and drug was released incrementally for the remainder of the monitored period. In all 
HMW ISIs tested, release plateaued at approximately 70% of total drug, and pre-loaded 
doxycycline released an additional 28% over the following 6 days. In LMW ISIs, the plateau 
ranged from 86-95% for 30% PLGA and from 63-74% in 40% PLGA. 40% LMW PLGA ISIs were 
tested with pre-loaded doxycycline, and after an initial 63% burst, release continued up to 87% 
by day 7. 
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Figure 5.7. Doxycycline release from A) HMW and B) LMW ISIs. D+S indicates that scaffolds were 
co-loaded with simvastatin and doxycycline. Data are mean ± standard deviation (n=3). 
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5.4. Discussion 
PBAE additives act as both porogens and drug delivery vehicles within the solid PLGA ISI 
matrix. As porogens,the 1-day mass loss of HMW-H and HMW-H/AH scaffolds indicated 
complete degradation of H6, which has an expected degradation time of 4-8 hours [70], while 
both HMW-AH and LMW-AH scaffolds exhibited a gradual mass loss through 10 days, which is 
twice the 5 day in vitro degradation time of AH6 PBAEs [253]. The difference is probably due to 
the PLGA matrix both limiting the accessibility of water to the embedded PBAE microparticles 
and physically restraining them from swelling, thus slowing degradation [80, 254]. There is 
evidence that PBAE swelling is restricted by comparing the microCT cutplanes and implant 
volumes between groups, in which HMW-H, which contains the most hydrophilic PBAE, swelled 
more gradually and to a smaller degree than HMW-H and HMW-H/AH formulations. 
Theoretically, H6 should achieve greater maximum swelling than AH6, and the maximum 
swelling point should occur at 4 hours and 36 hours, respectively [255]. HMW-H scaffolds likely 
had delayed degradation of the PBAE as well, however, the daily sampling frequency would not 
detect a difference unless the degradation period of H6, which typically degrades in 4-8 hours 
[70], was prolonged beyond 24 hours. The failure of HMW-Controls to swell beyond their initial 
mass suggests that the loss of NMP during precipitation exceeded the water uptake of the 
scaffolds. Conversely, LMW-Controls were capable of entrapping water in the core of the 
scaffolds due to their less hydrophobic nature, and the rapid decrease in wet mass after day 3 
was caused by the fragile PLGA skin rupturing, allowing the entrapped buffer to leak out. 
Interestingly, all HMW scaffolds containing PBAE microparticles swelled up to 250% of their 
original mass over a period of 30 days, while comparable LMW scaffolds swelled to a maximum 
of 150%. Again, LMW scaffolds were prone to rupture, which would allow water to escape, 
while the HMW scaffolds remained structurally sound as they swelled, and therefore 
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maintained a larger water capacity. Prior research on similar systems containing porogens such 
as sucrose or sodium chloride did not show such a dramatic mass changes [248], which suggests 
that the swelling behavior of PBAE hydrogel particles has a more profound effect on water 
uptake and retention than traditional porogens.  
PBAE microparticles also influence macro- and microstructural changes of ISIs as they 
degrade. HMW-Controls possessed surface-adjacent smaller pores and centrally-located 
macropores, which is typical of these implants because PLGA at the surface tends to precipitate 
rapidly, while the interior precipitates more gradually, allowing voids to coalesce [141]. PBAE 
microparticles caused the ISIs to adopt a porous network with no difference between surface or 
central pore sizes, because the homogeneous distribution of hydrogel microparticles acted as a 
template for a uniform PLGA microstructure. This hypothesis is supported by the rapid swelling 
and increase in accessible volume observed in all PBAE-containing ISIs. The lack of collapse in 
HMW-AH, -H, or H/AH implants implies that these homogeneously distributed hydrogel particles 
also play a role in stabilizing the implant structurally. In HMW-Controls, the largest pores 
collapsed, whereas in PBAE-containing scaffolds, with their uniform microstructures, were able 
to distribute stresses throughout the PLGA matrix and did not collapse. It has been previously 
demonstrated that varying the size and distribution of pores can dramatically alter mechanical 
properties of materials [256, 257]. The lattice-like PLGA network of PBAE-containing implants 
may also help explain the sustained mechanical resilience observed in HMW-AH implants even 
after the degradation period of the PBAE had passed. The increased porosity and accessible 
surface area of PBAE-containing ISIs offers many advantages when considering PLGA ISIs as 
potential scaffolds rather than simply drug delivery devices. In pre-formed PLGA scaffolds, larger 
accessible volume and surface area provides more opportunity for tissue ingrowth, and it is 
anticipated that PLGA ISIs will behave similarly in future cell culture or in vivo testing.  
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A persistent issue with antibiotic-releasing implants in periodontal applications is that 
the implant is not secure inside the periodontal pocket, which can lead to small pieces breaking 
off as the implant moves within the space [258]. Here, push-out forces were used to measure 
the interfacial strength between the implant surface and a simulated tissue pocket. The 
opposing trends observed in push-out force for HMW-Control compared to HMW-AH samples 
indicate that swelling of AH hydrogels can improve space-filling and pocket retention of 
implants. Even at the initial 3-day measurement, HMW-AH samples had significantly higher 
interfacial strength than controls, and this difference became even more pronounced as the 
incubation period increased. Although HMW PLGA does swell to a small degree as it degrades, 
this behavior is offset by the shrinkage of the implant during the precipitation phase, and the 
net result is that the interfacial strength remains negligible. On the other hand, AH hydrogels 
were observed to swell beyond 200% of their initial mass within 2 days in PBS (data not shown), 
and although this effect is probably muted due to the physical constraint within the PLGA 
matrix, there is enough of an effect to provide 4 to 10-fold higher interfacial strength than 
controls. Preliminary studies also showed no measurable adhesion between the gelatin surface 
and the implants (data not shown), so any differences in interfacial strength should be solely a 
result of the superior space-filling due to swelling of HMW-AH implants. LMW-AH scaffolds 
exhibited a similar benefit compared to LMW-Controls, though this difference was less 
pronounced due to the natural swelling behavior of LMW-Controls, which increased interfacial 
strength, and the rapid degradation of material, which caused both LMW-Controls and LMW-AH 
to decrease in strength over the 15 day period. A scaffold that expands to fill its injection site as 
it solidifies is less likely to cause irritation due to movement within the pocket. Furthermore, 
more contact area between the implant and the tissue means that the released drug has a 
shorter path to enter the gingival tissue, and it has a smaller likelihood of being washed away 
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due to fluid exchange in the crevicular fluid. Unfortunately, little information is available on the 
magnitude of stresses experienced within gingival soft tissue, although it is widely reported that 
the periodontal ligament is the soft tissue responsible for transmitting chewing force between 
the tooth and the underlying alveolar bone [259, 260]. Measurements of the stress in oral 
mucosal tissues under typical bite forces of denture wearers suggested that these tissues 
experiences compressive stresses ranging from 5 to 40 kPa during chewing [261]. According to 
these values, HMW-AH ISIs have initial interfacial strengths within that range, and within 6 days 
the interfacial strength exceeds the stress generated by a soft bite. HMW-Controls at every time 
point possessed interfacial strengths 1-2 orders of magnitude lower than these stress ranges. 
This data suggests that patients receiving HMW-AH ISIs may be able to chew food shortly after 
receiving treatment without danger of loosening the implant, while controls, which approximate 
clinically available treatments, are easily loosened and dislodged. This swelling-based, space-
filling approach is an alternative to other avenues that seek to reduce detachment by improving 
the adhesion between the polymer surface and surrounding tissue [249]. While the bioadhesion 
approach was observed in the first several hours following implantation, the PBAE-containing 
ISIs were demonstrated to improve pocket retention through a 15-day period. An interesting 
approach for future studies may be to incorporate both bioadhesive and swelling additives in 
order to provide acute attachment followed by prolonged space-filling.  
 Although these periodontal ISIs are not designed as load-bearing structures, they are 
subject to stresses, primarily due to chewing, which typically occurs at frequencies between 0.1 
and 1 Hz in humans [262]. The gelatin molds used in push-out studies had similar compressive 
modulus compared to gingival tissues in order to simulate a periodontal pocket (data not 
shown) [250]. It has been proposed that less stiff implants may reduce irritation due to the 
presence of material within the periodontal pocket [263]. PLGA deformed plastically and 
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became stiffer under compression even at low strains and only 30 compression cycles, while the 
modulus of HMW-AH and LMW-AH samples remained unchanged, indicating that PBAE 
additives preserve elasticity. In the commercially available Atridox® system, a dressing or 
adhesive is used to keep the implant in place, but there is also the concern that repeated 
compression cycles can cause the implants to break apart, allowing pieces of material to cause 
local irritation, or escape the periodontal pocket [264, 265]. Therefore, flossing and brushing are 
discouraged for up to a week following implantation, and patients are told to expect small 
pieces of material to break off [265]. Although neither control nor PBAE-containing ISIs broke 
apart during the timeframe or compression cycles observed, the 30-cycle modulus of HMW-
Controls was reduced dramatically between 9 and 15 days, and this difference would likely 
become more pronounced as time or compression cycles increased. HMW-AH and LMW-AH 
samples were less stiff and retained their modulus throughout cyclic compression, which 
suggests they are more suitable to withstand the dynamic mechanical environment of the 
periodontal tissue. HMW-Controls and LMW-Controls were more resilient during the initial 
compression cycle, yet they were consistently less resilient than corresponding AH-containing 
implants after 30 cycles, indicating that the PBAE hydrogel component helps preserve resilience. 
The lack of change for both modulus and resilience after cyclic loading is promising for the 
development of more mechanically suitable implants for the periodontal pocket. Dynamic 
mechanical analysis is required to assess viscoelastic properties for full lifespan of the implant, 
but this short-term cyclic compression data suggests that the addition of only 10% hydrogel 
particles can greatly improve the durability of these implants. As mentioned previously, the 
addition of PBAE microparticles led to a lattice-like PLGA microstructure, which should 
theoretically provide more resilience than the heterogeneous structure of the controls because 
there are no macropores, which appear to be the source of collapse in controls. Oral soft tissues 
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have compressive moduli ranging from 0.2 to 8 MPa [250, 266], and typical dental materials 
used to fill these soft tissues after extractions or other procedures have moduli on the order of 
1-20 MPa [267], which are both similar to the compressive properties of ISIs developed here.   
 Simvastatin release kinetics from both HMW and LMW ISIs were highly dependent on 
PBAE microparticle content. The larger burst in controls can be attributed to simvastatin 
dissolved in the NMP phase being rapidly lost during solvent exchange, which has been 
previously reported [81]. Because PBAEs swell even more freely in organic solvents, such as 
NMP, acetone, and ethanol, than in water, PBAE microparticles become swollen with NMP and 
simvastatin during the mixing phase prior to injection. These swollen microparticles act as an 
additional diffusive barrier to reduce initial burst, and once the initial hardening of the scaffold 
surface has occurred, simvastatin release is governed by both diffusion and PBAE degradation. 
The degradation profile of AH6 microparticles is reflected in the accelerated release rate of AH 
and H/AH scaffolds through day 13. The release profile of HMW-H/AH closely approximates the 
average of the HMW-H and HMW-AH curves, which suggests that the two hydrogels contribute 
independently to simvastatin release kinetics, and the results of their contributions are additive. 
Simvastatin release kinetics were more strongly affected by PBAE microparticle content in 30% 
LMW PLGA scaffolds than in 40% LMW PLGA scaffolds, and this difference is attributable to 
multiple factors. First, the higher PLGA content formulation is more viscous, which allows more 
rapid formation of a protective “skin” that slows solvent exchange and thus burst release. 
Second, 40% LMW ISIs contain more PLGA for equivalent injected masses when compared to 
30% LMW ISIs, which provides more polymer volume to entrap simvastatin, further limiting 
burst. Interestingly, AH6 degradation did not appear to accelerate simvastatin release in LMW 
scaffolds as dramatically as it did in HMW scaffolds for the first 10 days. This may be due to the 
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faster degradation time and relatively higher hydrophilicity of LMW PLGA, which allows faster 
simvastatin release from the PLGA phase and masks the contribution of AH6-mediated release.  
 Release kinetics of freely-mixed doxycycline from HMW and LMW ISIs were unaffected 
by the addition of PBAE microparticles, however pre-loading doxycycline into AH6 microparticles 
provided a measure of control. The lack of additional doxycycline release after the initial burst in 
freely-mixed cases is probably due to the entrapment of remaining drug in the PLGA phase, and 
because doxycycline is substantially more hydrophilic than simvastatin, it has low mobility 
through the hydrophobic PLGA matrix. This plateau effect is undesirable for antibiotic delivery, 
because bacteria surviving the initial burst will be free to re-colonize. By pre-loading doxycycline 
into AH6 PBAE microparticles, the initial burst was followed by continuous release of remaining 
drug through 1 week, which is consistent with systemic doxycycline regimens of 1 week 
following scaling and root planing.  
5.5. Conclusions 
PLGA ISIs formulated with PBAE microparticle additives provide multiple advantages 
over existing periodontal ISIs. These composite ISIs are more resilient and are retained more 
firmly in simulated gingival tissue than PLGA alone, so there will be a lower risk of the implant 
deforming, loosening, and breaking apart prematurely, which is a concern with existing systems. 
Additionally, PBAE microparticles offer a secondary means of controlling drug release kinetics, 
and multiple drugs with independent release profiles can be delivered, instead of the single-
drug systems that are currently available. Future studies will focus on the potential of these 
PBAE-containing ISIS to act as scaffolds for tissue regeneration, because the high porosity and 
open pore network is suitable for tissue ingrowth.  
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Chapter 6 Summary and Conclusions 
 In this dissertation, hydrogel and hydroxyapatite additives were used to improve the 
properties of PLGA ISIs, and provide an early proof of concept that these materials can also 
serve a role as scaffolds rather than pure drug delivery devices.  
First, the orthopedic potential of composite PLGA/PBAE/HA ISIs was investigated. Both 
simvastatin and clodronate were released with reduced burst compared to controls, which 
demonstrated that drug release can be controlled independently of traditional techniques that 
modify the precipitation rate. These results suggest that a modular system can be developed, 
where a single PLGA solution can be easily modified to provide tailored release kinetics simply 
through the addition of HA and drug-loaded PBAE microparticles. Hydroxyapatite was then 
shown to control mechanical properties of these ISIs, and this information was used to develop 
a formulation that was mechanically similar to healthy trabecular bone. Importantly, the 
proposed system would be locally injectable into the intertrabecular space within the femoral 
head, which eliminates the need for invasive surgery and removal of tissue. Instead, the ex vivo 
injections showed the feasibility of this system to mechanically support bone within the femoral 
head while the drug release component takes effect. The orthopedic scaffolds developed in 
Chapters 3 and 4 have the potential to fill an important role in the treatment of osteonecrosis, 
because existing techniques are invasive and have limited effectiveness once the disease has 
weakened the bone enough to cause collapse.  
PBAE hydrogel microparticles were also shown to improve PLGA ISIs for soft tissue 
applications, specifically in the oral gingiva. ISIs capable of co-delivery of doxycycline for 1 week 
and simvastatin for 30 to 90 days were developed, which has implications in cases of advanced 
periodontitis where extensive bone loss has occurred. Additionally, the PBAE additives improved 
interfacial strength in a simulated periodontal pocket due to swelling, and were responsible for 
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reducing stiffness and increasing durability of solidified ISIs. Ultimately, the PBAE-containing ISIs 
are a more suitable match for soft tissue, and also provide dramatically more accessible volume 
and porosity, which is advantageous for tissue ingrowth.  
From a tissue engineering perspective, current PLGA ISIs are nonfunctional as scaffolds, 
with closed pores, a heterogeneous microarchitecture, and poor mechanical properties. In 
preformed, implantable PLGA scaffolds, additives are frequently used as porogens or to 
facilitate drug delivery, and that approach was employed here to improve numerous properties 
of PLGA ISIs. The resulting PBAE-containing ISIs are a versatile drug delivery platform with 
tremendous potential as “all in one” treatments that can be adapted to different tissues simply 
by modifying the additives. 
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